

Siegfried Kasper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1570572/publications.pdf>

Version: 2024-02-01

876
papers

36,822
citations

3334

91
h-index

8866

145
g-index

1004
all docs

1004
docs citations

1004
times ranked

24162
citing authors

#	ARTICLE	IF	CITATIONS
1	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. <i>American Journal of Psychiatry</i> , 2013, 170, 1249-1262.	7.2	579
2	Epidemiological Findings of Seasonal Changes in Mood and Behavior. <i>Archives of General Psychiatry</i> , 1989, 46, 823.	12.3	577
3	A Pooled Analysis of 2 Placebo-Controlled 18-Month Trials of Lamotrigine and Lithium Maintenance in Bipolar I Disorder. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 432-441.	2.2	518
4	Social Functioning in Depression. <i>Journal of Clinical Psychiatry</i> , 2000, 61, 268-275.	2.2	464
5	Clinical Factors Associated With Treatment Resistance in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1062-1070.	2.2	407
6	CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. <i>Acta Psychiatrica Scandinavica</i> , 2001, 104, 173-192.	4.5	367
7	Reduced resting-state functional connectivity between amygdala and orbitofrontal cortex in social anxiety disorder. <i>NeuroImage</i> , 2011, 56, 881-889.	4.2	353
8	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 154-219.	2.6	344
9	Updated European Consensus Statement on diagnosis and treatment of adult ADHD. <i>European Psychiatry</i> , 2019, 56, 14-34.	0.2	330
10	Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 77-84.	2.4	327
11	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 81-109.	2.6	322
12	Circadian Clock-Related Polymorphisms in Seasonal Affective Disorder and their Relevance to Diurnal Preference. <i>Neuropsychopharmacology</i> , 2003, 28, 734-739.	5.4	307
13	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 85-116.	2.6	302
14	Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 77, 317-326.	6.1	296
15	The Serotonin-1A Receptor in Anxiety Disorders. <i>Biological Psychiatry</i> , 2009, 66, 627-635.	1.3	285
16	Neurobiological and Clinical Effects of the Antidepressant Tianeptine. <i>CNS Drugs</i> , 2008, 22, 15-26.	5.9	281
17	Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 22-31.	2.1	280
18	Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder. <i>Biological Psychiatry</i> , 2007, 61, 1081-1089.	1.3	276

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 325-337.	2.1	272
20	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , 2021, 178, 383-399.	7.2	270
21	Prognosis and improved outcomes in major depression: a review. <i>Translational Psychiatry</i> , 2019, 9, 127.	4.8	262
22	Three circadian clock genes Per2, Arntl, and Npas2 contribute to winter depression. <i>Annals of Medicine</i> , 2007, 39, 229-238.	3.8	234
23	Phototherapy in Individuals With and Without Subsyndromal Seasonal Affective Disorder. <i>Archives of General Psychiatry</i> , 1989, 46, 837.	12.3	220
24	Reward and the serotonergic system. <i>Neuroscience</i> , 2010, 166, 1023-1035.	2.3	220
25	Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 109-120.	2.2	218
26	A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. <i>European Psychiatry</i> , 2002, 17, 331s-340s.	0.2	214
27	Bright-Light Therapy in the Treatment of Mood Disorders. <i>Neuropsychobiology</i> , 2011, 64, 152-162.	1.9	205
28	Assessment and management of agitation in psychiatry: Expert consensus. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 86-128.	2.6	204
29	Reboxetine: the first selective noradrenaline re-uptake inhibitor. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 771-782.	1.8	202
30	Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 661-73.	2.1	197
31	Association Between Serotonin Transporter Gene Promoter Polymorphism(5HTTLPR) and Behavioral Responses to Tryptophan Depletion in Healthy Women With and Without Family History of Depression. <i>Archives of General Psychiatry</i> , 2002, 59, 613.	12.3	193
32	Application of transcranial magnetic stimulation in treatment of drug-resistant major depression-a report of two cases. <i>Human Psychopharmacology</i> , 1993, 8, 361-365.	1.5	191
33	Efficacy and Safety of Pregabalin in the Treatment of Generalized Anxiety Disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 771-782.	2.2	191
34	[123I]- β -CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. <i>Biological Psychiatry</i> , 2000, 47, 482-489.	1.3	185
35	Rediscovering Trazodone for the Treatment of Major Depressive Disorder. <i>CNS Drugs</i> , 2012, 26, 1033-1049.	5.9	170
36	Partial Response and Nonresponse to Antidepressant Therapy. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 826-837.	2.2	170

#	ARTICLE	IF	CITATIONS
37	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Eating Disorders. World Journal of Biological Psychiatry, 2011, 12, 400-443.	2.6	168
38	The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. European Neuropsychopharmacology, 2002, 12, 461-475.	0.7	161
39	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Bipolar Disorders, Part I: Treatment of Bipolar Depression. World Journal of Biological Psychiatry, 2002, 3, 115-124.	2.6	161
40	Lavender oil preparation Silexan is effective in generalized anxiety disorder – a randomized, double-blind comparison to placebo and paroxetine. International Journal of Neuropsychopharmacology, 2014, 17, 859-869.	2.1	161
41	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. World Journal of Biological Psychiatry, 2002, 3, 171-199.	2.6	155
42	Transcranial magnetic stimulation (TMS) in the treatment of major depression – a pilot study. Human Psychopharmacology, 1995, 10, 305-310.	1.5	152
43	The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 3: The clinical guidelines.. International Journal of Neuropsychopharmacology, 2017, 20, pyw109.	2.1	151
44	Bright light therapy stabilizes the antidepressant effect of partial sleep deprivation. Biological Psychiatry, 1996, 39, 16-21.	1.3	149
45	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World Journal of Biological Psychiatry, 2003, 4, 5-13.	2.6	148
46	Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. International Clinical Psychopharmacology, 2001, 16, 75-86.	1.7	147
47	Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2020, 81, .	2.2	145
48	Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction, 1999, 94, 1337-1347.	3.3	144
49	Effects of Tryptophan Depletion vs Catecholamine Depletion in Patients With Seasonal Affective Disorder in Remission With Light Therapy. Archives of General Psychiatry, 1998, 55, 524.	12.3	143
50	Anger Attacks in Depression – Evidence for a Male Depressive Syndrome. Psychotherapy and Psychosomatics, 2005, 74, 303-307.	8.8	142
51	Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. International Journal of Neuropsychopharmacology, 2013, 16, 557-574.	2.1	141
52	The serotonin transporter in psychiatric disorders: insights from PET imaging. Lancet Psychiatry, the, 2015, 2, 743-755.	7.4	140
53	Regional sex differences in grey matter volume are associated with sex hormones in the young adult human brain. NeuroImage, 2010, 49, 1205-1212.	4.2	139
54	Escitalopram in the treatment of social anxiety disorder. British Journal of Psychiatry, 2005, 186, 222-226.	2.8	137

#	ARTICLE	IF	CITATIONS
55	Which antidepressants have demonstrated superior efficacy? A review of the evidence. <i>International Clinical Psychopharmacology</i> , 2007, 22, 323-329.	1.7	137
56	Evaluation of seasonality in six clinical populations and two normal populations. <i>Journal of Psychiatric Research</i> , 1991, 25, 75-87.	3.1	136
57	Abnormal Pituitary-Adrenal Responses to Corticotropin-Releasing Hormone in Patients with Seasonal Affective Disorder: Clinical and Pathophysiological Implications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 1382-1387.	3.6	136
58	Quantification of Metabolic Differences in the Frontal Brain of Depressive Patients and Controls Obtained by 1H-MRS at 3 Tesla. <i>Investigative Radiology</i> , 2003, 38, 403-408.	6.2	136
59	Circuit Mechanisms of Reward, Anhedonia, and Depression. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 105-118.	2.1	135
60	[123I] β -CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa. <i>Biological Psychiatry</i> , 2001, 49, 326-332.	1.3	134
61	Inverse Relationship Between Serotonin 5-HT _{1A} Receptor Binding and Anxiety: A [11C]WAY-100635 PET Investigation in Healthy Volunteers. <i>American Journal of Psychiatry</i> , 2001, 158, 1326-1328.	7.2	134
62	The identification, assessment and management of difficult-to-treat depression: An international consensus statement. <i>Journal of Affective Disorders</i> , 2020, 267, 264-282.	4.1	133
63	Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants. <i>International Clinical Psychopharmacology</i> , 1995, 9, 33-40.	1.7	130
64	Brain Serotonin 5-HT _{1A} Receptor Binding in Schizophrenia Measured by Positron Emission Tomography and [11C]WAY-100635. <i>Archives of General Psychiatry</i> , 2002, 59, 514.	12.3	130
65	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 2-58.	2.6	128
66	Effects of Tryptophan Depletion on Drug-Free Patients With Seasonal Affective Disorder During a Stable Response to Bright Light Therapy. <i>Archives of General Psychiatry</i> , 1997, 54, 133.	12.3	127
67	Silexan, an orally administered <i>Lavandula</i> oil preparation, is effective in the treatment of β -subsyndromal™ anxiety disorder: a randomized, double-blind, placebo controlled trial. <i>International Clinical Psychopharmacology</i> , 2010, 25, 277-287.	1.7	126
68	Normative database of the serotonergic system in healthy subjects using multi-tracer PET. <i>NeuroImage</i> , 2012, 63, 447-459.	4.2	126
69	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part III: Maintenance Treatment. <i>World Journal of Biological Psychiatry</i> , 2004, 5, 120-135.	2.6	124
70	Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. <i>NeuroImage</i> , 2012, 63, 874-881.	4.2	124
71	β -CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. <i>Journal of Neural Transmission</i> , 1995, 100, 247-256.	2.8	123
72	Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients. <i>European Neuropsychopharmacology</i> , 1999, 10, 17-20.	0.7	120

#	ARTICLE	IF	CITATIONS
73	Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. <i>Journal of Affective Disorders</i> , 2000, 60, 61-74.	4.1	118
74	Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. <i>Schizophrenia Research</i> , 1998, 32, 101-106.	2.0	117
75	No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. <i>Biological Psychiatry</i> , 2001, 50, 8-12.	1.3	117
76	Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. <i>European Neuropsychopharmacology</i> , 2010, 20, 747-765.	0.7	116
77	Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 1-48.	3.2	113
78	Comparative Efficacy of Antidepressants. <i>Drugs</i> , 1992, 43, 11-23.	10.9	111
79	Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: A randomized cross-over study. <i>NeuroImage</i> , 2010, 49, 1161-1170.	4.2	111
80	European Group for the Study of Resistant Depression (GSRD) – Where have we gone so far: Review of clinical and genetic findings. <i>European Neuropsychopharmacology</i> , 2012, 22, 453-468.	0.7	111
81	Serotonin 5-HT1A Receptor Binding Potential Declines with Age as Measured by [11C]WAY-100635 and PET. <i>Neuropsychopharmacology</i> , 2001, 24, 522-530.	5.4	110
82	Differential modulation of the default mode network via serotonin-1A receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2619-2624.	7.1	109
83	Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. <i>International Clinical Psychopharmacology</i> , 2007, 22, 283-291.	1.7	108
84	A polymorphism (5-HTTLPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder. <i>Molecular Psychiatry</i> , 2003, 8, 942-946.	7.9	103
85	Management of mild cognitive impairment (MCI): The need for national and international guidelines. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 579-594.	2.6	100
86	Agomelatine in the treatment of seasonal affective disorder. <i>Psychopharmacology</i> , 2007, 190, 575-579.	3.1	99
87	Reduced default mode network suppression during a working memory task in remitted major depression. <i>Journal of Psychiatric Research</i> , 2015, 64, 9-18.	3.1	99
88	Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. <i>Molecular Psychiatry</i> , 2013, 18, 93-100.	7.9	98
89	Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. <i>Psychological Medicine</i> , 2001, 31, 1467-1473.	4.5	97
90	Silexan in anxiety disorders: Clinical data and pharmacological background. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 412-420.	2.6	96

#	ARTICLE	IF	CITATIONS
91	Genome scan for susceptibility loci for schizophrenia and bipolar disorder. <i>Biological Psychiatry</i> , 2002, 52, 40-52.	1.3	95
92	Guided self-help versus cognitive-behavioral group therapy in the treatment of bulimia nervosa. <i>International Journal of Eating Disorders</i> , 2004, 35, 522-537.	4.0	95
93	White Matter Microstructure in Transsexuals and Controls Investigated by Diffusion Tensor Imaging. <i>Journal of Neuroscience</i> , 2014, 34, 15466-15475.	3.6	93
94	Ketamine-Induced Modulation of the Thalamo-Cortical Network in Healthy Volunteers As a Model for Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv040.	2.1	93
95	Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. <i>European Neuropsychopharmacology</i> , 2019, 29, 971-985.	0.7	93
96	Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 78-88.	4.5	92
97	Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5 tesla. <i>Journal of Psychiatric Research</i> , 1998, 32, 411-420.	3.1	91
98	Escitalopram in the Treatment of Depressed Elderly Patients. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 884-891.	1.2	91
99	Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers. <i>Neuropsychopharmacology</i> , 2008, 33, 1633-1641.	5.4	91
100	Review of quetiapine and its clinical applications in schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 783-801.	1.8	90
101	Evidence-based pharmacotherapy of treatment-resistant unipolar depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 13-23.	2.4	90
102	Results of the European Group for the Study of Resistant Depression (GSRD) – basis for further research and clinical practice. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 427-448.	2.6	89
103	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 160-187.	2.6	88
104	Neurotransmitters and Electroconvulsive Therapy. <i>Journal of ECT</i> , 2014, 30, 116-121.	0.6	88
105	Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders. <i>Molecular Psychiatry</i> , 2009, 14, 1040-1050.	7.9	87
106	Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging. <i>NeuroImage</i> , 2018, 176, 259-267.	4.2	87
107	St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. <i>Psychopharmacology</i> , 2002, 164, 294-300.	3.1	86
108	Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression. <i>International Clinical Psychopharmacology</i> , 1996, 11, 35-40.	1.7	85

#	ARTICLE	IF	CITATIONS
109	Enhanced Serotonin Transporter Function during Depression in Seasonal Affective Disorder. <i>Neuropsychopharmacology</i> , 2008, 33, 1503-1513.	5.4	85
110	Aggression is related to frontal serotonin 5-HT _{1A} receptor distribution as revealed by PET in healthy subjects. <i>Human Brain Mapping</i> , 2009, 30, 2558-2570.	3.6	84
111	Administration of ketamine for unipolar and bipolar depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 2-12.	2.4	84
112	Do SSRIs or antidepressants in general increase suicidality?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 3-23.	3.2	83
113	Switching Antidepressant Class Does Not Improve Response or Remission in Treatment-Resistant Depression. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 512-516.	1.4	83
114	Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pii047.	2.1	83
115	Neurobiology of Seasonal Affective Disorder and Phototherapy. <i>Journal of Biological Rhythms</i> , 1988, 3, 135-154.	2.6	82
116	In vivo 123 I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. <i>Psychopharmacology</i> , 1999, 141, 175-181.	3.1	82
117	The effects of light therapy on mini-mental state examination scores in demented patients. <i>Biological Psychiatry</i> , 2001, 50, 725-727.	1.3	82
118	Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. <i>International Clinical Psychopharmacology</i> , 2009, 24, 87-96.	1.7	82
119	The relevance of "mixed anxiety and depression" as a diagnostic category in clinical practice. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 725-736.	3.2	82
120	Cognitive Performance Test: A New Approach to Functional Assessment in Alzheimer's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1994, 7, 46-54.	2.3	81
121	Receptor and Transporter Imaging Studies in Schizophrenia, Depression, Bulimia and Tourette's Disorder—Implications for Psychopharmacology. <i>World Journal of Biological Psychiatry</i> , 2002, 3, 133-146.	2.6	80
122	Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 117-126.	2.6	78
123	Low frontal electroencephalographic coherence in neuroleptic-free schizophrenic patients. <i>Biological Psychiatry</i> , 1998, 44, 438-447.	1.3	77
124	Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. <i>Psychological Medicine</i> , 1998, 28, 923-933.	4.5	77
125	Superior efficacy of St John's wort extract WSÂ®5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN7727298]. <i>BMC Medicine</i> , 2006, 4, 14.	5.5	77
126	The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. <i>European Neuropsychopharmacology</i> , 2015, 25, 441-453.	0.7	77

#	ARTICLE	IF	CITATIONS
127	The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm. <i>International Journal of Neuropsychopharmacology</i> , 2016, 20, pyw100.	2.1	77
128	Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. <i>Journal of Psychiatric Research</i> , 2017, 91, 1-13.	3.1	77
129	The citalopram challenge test in patients with major depression and in healthy controls. <i>Psychiatry Research</i> , 1999, 88, 75-88.	3.3	76
130	In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. <i>Psychopharmacology</i> , 2006, 188, 263-272.	3.1	76
131	Refining Prediction in Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 16m11385.	2.2	76
132	Hypericum perforatum - a Review of Clinical Studies. <i>Pharmacopsychiatry</i> , 2001, 34, 51-55.	3.3	75
133	High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People. <i>Biological Psychiatry</i> , 2015, 78, 525-533.	1.3	75
134	Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. <i>Psychopharmacology</i> , 2002, 162, 42-49.	3.1	74
135	Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. <i>International Clinical Psychopharmacology</i> , 2006, 21, 105-110.	1.7	74
136	Brain-derived neurotrophic factor (BDNF)â€™Epigenetic regulation in unipolar and bipolar affective disorder. <i>Journal of Affective Disorders</i> , 2014, 168, 399-406.	4.1	74
137	Second-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled Trials. <i>Psychotherapy and Psychosomatics</i> , 2015, 84, 110-116.	8.8	74
138	CARBOHYDRATE-DEFICIENT TRANSFERRIN AS A MARKER OF ALCOHOL INTAKE: A STUDY WITH HEALTHY SUBJECTS. <i>Alcohol and Alcoholism</i> , 1996, 31, 265-271.	1.6	73
139	Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. <i>Journal of Affective Disorders</i> , 2016, 189, 224-232.	4.1	73
140	A New Prediction Model for Evaluating Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 215-222.	2.2	73
141	A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 507-522.	2.1	72
142	Lateralization of the serotonin-1A receptor distribution in language areas revealed by PET. <i>NeuroImage</i> , 2009, 45, 598-605.	4.2	72
143	Structural changes in amygdala nuclei, hippocampal subfields and cortical thickness following electroconvulsive therapy in treatment-resistant depression: longitudinal analysis. <i>British Journal of Psychiatry</i> , 2019, 214, 159-167.	2.8	71
144	Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. <i>International Clinical Psychopharmacology</i> , 1995, 10, 25-35.	1.7	70

#	ARTICLE	IF	CITATIONS
145	Seasonal variation of availability of serotonin transporter binding sites in healthy female subjects as measured by [¹²³ I]-2 β -carbomethoxy-3 β -(4-iodophenyl)tropane and single photon emission computed tomography. <i>Biological Psychiatry</i> , 2000, 47, 158-160.	1.3	70
146	Effects of light treatment on core body temperature in seasonal affective disorder. <i>Biological Psychiatry</i> , 1990, 27, 39-50.	1.3	69
147	Actigraphy in Patients with Seasonal Affective Disorder and Healthy Control Subjects Treated with Light Therapy. <i>Biological Psychiatry</i> , 2005, 58, 331-336.	1.3	69
148	Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. <i>International Clinical Psychopharmacology</i> , 2009, 24, 250-256.	1.7	69
149	Cerebral CT findings in male opioid-dependent patients: Stereological, planimetric and linear measurements. <i>Psychiatry Research - Neuroimaging</i> , 1998, 83, 139-147.	1.8	68
150	Genome Scan for Susceptibility Loci for Schizophrenia. <i>Neuropsychobiology</i> , 2000, 42, 175-182.	1.9	68
151	A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. <i>Psychopharmacology</i> , 2004, 171, 390-397.	3.1	68
152	Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders. <i>European Neuropsychopharmacology</i> , 2015, 25, 763-772.	0.7	68
153	Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. <i>European Neuropsychopharmacology</i> , 1993, 3, 13-21.	0.7	67
154	Cognitive effects and antipsychotic treatment. <i>Psychoneuroendocrinology</i> , 2003, 28, 27-38.	2.7	67
155	Brain-derived neurotrophic factor gene polymorphisms. <i>International Clinical Psychopharmacology</i> , 2011, 26, 1-10.	1.7	67
156	Nocturnal TSH and prolactin secretion during sleep deprivation and prediction of antidepressant response in patients with major depression. <i>Biological Psychiatry</i> , 1988, 24, 631-641.	1.3	66
157	Testosterone in the brain: Neuroimaging findings and the potential role for neuropsychopharmacology. <i>European Neuropsychopharmacology</i> , 2013, 23, 79-88.	0.7	66
158	Structural Connectivity Networks of Transgender People. <i>Cerebral Cortex</i> , 2015, 25, 3527-3534.	2.9	66
159	IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. <i>Psychopharmacology</i> , 1997, 133, 323-328.	3.1	65
160	The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials. <i>Psychotherapy and Psychosomatics</i> , 2020, 89, 17-24.	8.8	65
161	The Anticholinergic Biperiden in Depressive Disorders. <i>Pharmacopsychiatry</i> , 1981, 14, 195-198.	3.3	64
162	Brightening Depression. <i>Science</i> , 2004, 303, 467-469.	12.6	64

#	ARTICLE	IF	CITATIONS
163	A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. <i>European Neuropsychopharmacology</i> , 2008, 18, 122-127.	0.7	64
164	Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. <i>Journal of Affective Disorders</i> , 2013, 151, 209-219.	4.1	64
165	Quantification of Task-Specific Glucose Metabolism with Constant Infusion of ¹⁸ F-FDG. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1933-1940.	5.0	64
166	Monoaminergic function in the pathogenesis of seasonal affective disorder. <i>International Journal of Neuropsychopharmacology</i> , 2001, 4, 409-20.	2.1	63
167	Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 739-748.	2.1	63
168	Default mode network deactivation during emotion processing predicts early antidepressant response. <i>Translational Psychiatry</i> , 2017, 7, e1008-e1008.	4.8	63
169	Contrasts between symptoms of summer depression and winter depression. <i>Journal of Affective Disorders</i> , 1991, 23, 173-183.	4.1	62
170	Anxiety disorders: under-diagnosed and insufficiently treated. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006, 10, 3-9.	2.4	62
171	Application of image-derived and venous input functions in major depression using [carbonyl- ¹¹ C]WAY-100635. <i>Nuclear Medicine and Biology</i> , 2013, 40, 371-377.	0.6	62
172	Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep – A randomized, placebo-controlled trial. <i>European Neuropsychopharmacology</i> , 2015, 25, 1960-1967.	0.7	62
173	Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer. <i>Psychological Medicine</i> , 1998, 28, 257-264.	4.5	61
174	Effective open-label treatment of Tourette's disorder with olanzapine. <i>International Clinical Psychopharmacology</i> , 2000, 15, 23-28.	1.7	61
175	A Risk-Benefit Assessment of Mirtazapine in the Treatment of Depression. <i>Drug Safety</i> , 1997, 17, 251-264.	3.2	60
176	Effects of sunshine on suicide rates. <i>Comprehensive Psychiatry</i> , 2012, 53, 535-539.	3.1	60
177	[¹²³ I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. <i>American Journal of Psychiatry</i> , 1996, 153, 183-190.	7.2	59
178	Placebo-controlled studies in depression: necessary, ethical and feasible. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003, 253, 22-28.	3.2	59
179	The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl- ¹¹ C]WAY-100635. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 2159-2168.	6.4	59
180	Additive Gene-Environment Effects on Hippocampal Structure in Healthy Humans. <i>Journal of Neuroscience</i> , 2014, 34, 9917-9926.	3.6	59

#	ARTICLE	IF	CITATIONS
181	Reduced task durations in functional PET imaging with [18F]FDG approaching that of functional MRI. <i>NeuroImage</i> , 2018, 181, 323-330.	4.2	59
182	Transcultural Study of Schizophrenic Delusions. <i>Psychopathology</i> , 1998, 31, 59-68.	1.5	58
183	Effects of Tryptophan Depletion in Drug-Free Depressed Patients Who Responded to Total Sleep Deprivation. <i>Archives of General Psychiatry</i> , 1998, 55, 167.	12.3	58
184	Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. <i>Psychopharmacology</i> , 2007, 191, 333-339.	3.1	58
185	The role of pharmacogenetics in the treatment of depression and anxiety disorders. <i>International Clinical Psychopharmacology</i> , 2009, 24, 277-288.	1.7	58
186	The effects of phototherapy in the general population. <i>Journal of Affective Disorders</i> , 1990, 18, 211-219.	4.1	57
187	Pathological Regional Cerebral Blood Flow in Opiate-Dependent Patients during Withdrawal: A HMPAO-SPECT Study. <i>Neuropsychobiology</i> , 1998, 37, 194-199.	1.9	57
188	Osteopenia in anorexia nervosa: specific mechanisms of bone loss. <i>Journal of Psychiatric Research</i> , 1999, 33, 349-356.	3.1	57
189	Possible association between childhood absence epilepsy and the gene encoding GABRB3. <i>Biological Psychiatry</i> , 1999, 46, 997-1002.	1.3	57
190	Evaluation of the Two-Way Communication Checklist as a clinical intervention. <i>British Journal of Psychiatry</i> , 2004, 184, 79-83.	2.8	57
191	Light-dependent alteration of serotonin-1A receptor binding in cortical and subcortical limbic regions in the human brain. <i>World Journal of Biological Psychiatry</i> , 2012, 13, 413-422.	2.6	57
192	White matter hyperintensities and chronicity of depression. <i>Journal of Psychiatric Research</i> , 2005, 39, 285-293.	3.1	56
193	Current issues in bipolar disorder: A critical review. <i>European Neuropsychopharmacology</i> , 2007, 17, 687-695.	0.7	56
194	The hidden third: improving outcome in treatment-resistant depression. <i>Journal of Psychopharmacology</i> , 2012, 26, 587-602.	4.0	56
195	Suicidal Tendencies as a Complication of Light Therapy for Seasonal Affective Disorder. <i>Journal of Clinical Psychiatry</i> , 1997, 58, 389-392.	2.2	56
196	Dexamethasone suppression test in a pluri-diagnostic approach: its relationship to psychopathological and clinical variables. <i>Acta Psychiatrica Scandinavica</i> , 1983, 68, 31-37.	4.5	55
197	Fully exploratory network independent component analysis of the 1000 functional connectomes database. <i>Frontiers in Human Neuroscience</i> , 2012, 6, 301.	2.0	55
198	Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 86-119.	2.6	55

#	ARTICLE	IF	CITATIONS
199	Non-association of dopamine D4 and D2 receptor genes with personality in healthy individuals. <i>Psychiatric Genetics</i> , 2000, 10, 131-137.	1.1	54
200	A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. <i>International Clinical Psychopharmacology</i> , 2001, 16, 253-263.	1.7	54
201	Sex-specific predictors of criminal recidivism in a representative sample of incarcerated youth. <i>Comprehensive Psychiatry</i> , 2009, 50, 400-407.	3.1	54
202	Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 1129-1143.	2.1	54
203	Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET. <i>NeuroImage</i> , 2014, 88, 252-262.	4.2	54
204	Efficacy of Silexan in mixed anxietyâ€“depression â€“ A randomized, placebo-controlled trial. <i>European Neuropsychopharmacology</i> , 2016, 26, 331-340.	0.7	54
205	Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD). <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 539-549.	2.1	54
206	Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. <i>British Journal of Psychiatry</i> , 2019, 214, 27-35.	2.8	54
207	Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. <i>European Neuropsychopharmacology</i> , 2001, 11, 307-321.	0.7	53
208	Suicide by antidepressant intoxication identified at autopsy in Vienna from 1991â€“1997: the favourable consequences of the increasing use of SSRIs. <i>European Neuropsychopharmacology</i> , 2000, 10, 133-142.	0.7	52
209	Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2001, 16, 357-361.	1.7	52
210	Escitalopram Enhances the Association of Serotonin-1A Autoreceptors to Heteroreceptors in Anxiety Disorders. <i>Journal of Neuroscience</i> , 2010, 30, 14482-14489.	3.6	52
211	Pregabalin for generalized anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2017, 32, 49-55.	1.7	52
212	Sertindole and dopamine D 2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123 I-HBZM SPECT study. <i>Psychopharmacology</i> , 1998, 136, 367-373.	3.1	51
213	Risperidone and olanzapine. <i>International Clinical Psychopharmacology</i> , 1998, 13, 253-262.	1.7	51
214	The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a caseâ€“control association study. <i>International Clinical Psychopharmacology</i> , 2010, 25, 218-227.	1.7	51
215	Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder â€“ evidence from clinical trials. <i>Wiener Medizinische Wochenschrift</i> , 2010, 160, 547-556.	1.1	51
216	Cardiovascular Adverse Reactions During Antidepressant Treatment: A Drug Surveillance Report of German-Speaking Countries Between 1993 and 2010. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu080-pyu080.	2.1	51

#	ARTICLE	IF	CITATIONS
217	Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder. <i>Journal of Affective Disorders</i> , 2001, 63, 239-242.	4.1	50
218	Attenuated serotonin transporter association between dorsal raphe and ventral striatum in major depression. <i>Human Brain Mapping</i> , 2014, 35, 3857-3866.	3.6	50
219	Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers – A pharmacoepidemiological cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2016, 26, 1960-1971.	0.7	50
220	Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 48.	2.0	50
221	Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999, 249, S83-S89.	3.2	49
222	Opioid Addiction Changes Cerebral Blood Flow Symmetry. <i>Neuropsychobiology</i> , 2002, 45, 67-73.	1.9	49
223	Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. <i>International Clinical Psychopharmacology</i> , 2009, 24, 119-125.	1.7	49
224	Effects of Silexan on the Serotonin-1A Receptor and Microstructure of the Human Brain: A Randomized, Placebo-Controlled, Double-Blind, Cross-Over Study with Molecular and Structural Neuroimaging. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu063-pyu063.	2.1	49
225	Escitalopram in the Treatment of Depressed Elderly Patients. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 884-891.	1.2	49
226	Reconfiguration of functional brain networks and metabolic cost converge during task performance. <i>ELife</i> , 2020, 9, .	6.0	49
227	Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 424-455.	2.6	49
228	No change in striatal dopamine re-uptake site density in psychotropic drug naive and in currently treated Tourette’s disorder patients: a [123I]- β -CIT SPECT-study. <i>European Neuropsychopharmacology</i> , 2001, 11, 69-74.	0.7	48
229	Gray matter and intrinsic network changes in the posterior cingulate cortex after selective serotonin reuptake inhibitor intake. <i>NeuroImage</i> , 2014, 84, 236-244.	4.2	48
230	In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. <i>European Neuropsychopharmacology</i> , 1999, 9, 177-179.	0.7	47
231	Continuation and long-term maintenance treatment with Hypericum extract WSÂ® 5570 after recovery from an acute episode of moderate depression – A double-blind, randomized, placebo controlled long-term trial. <i>European Neuropsychopharmacology</i> , 2008, 18, 803-813.	0.7	47
232	The Diagnosis and Treatment of Generalized Anxiety Disorder. <i>Deutsches A&#x0308;rztblatt International</i> , 2013, 110, 300-9; quiz 310.	0.9	47
233	Testosterone affects language areas of the adult human brain. <i>Human Brain Mapping</i> , 2016, 37, 1738-1748.	3.6	47
234	Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). <i>European Neuropsychopharmacology</i> , 2018, 28, 752-760.	0.7	47

#	ARTICLE	IF	CITATIONS
235	Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. <i>American Journal of Psychiatry</i> , 1997, 154, 1153-1155.	7.2	46
236	Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration. <i>Psychoneuroendocrinology</i> , 2016, 74, 371-379.	2.7	46
237	Response to Total Sleep Deprivation Before and During Treatment with Fluvoxamine or Maprotiline in Patients with Major Depression - Results of a Double-Blind Study. <i>Pharmacopsychiatry</i> , 1990, 23, 135-142.	3.3	45
238	Treatment of seasonal affective disorder. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1039-1048.	2.8	45
239	A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. <i>Journal of Affective Disorders</i> , 2011, 128, 56-63.	4.1	45
240	An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review. <i>International Journal of Psychiatry in Clinical Practice</i> , 2013, 17, 15-22.	2.4	45
241	Antidepressant efficacy of agomelatine versus SSRI/SNRI. <i>International Clinical Psychopharmacology</i> , 2013, 28, 12-19.	1.7	45
242	Therapeutic efficacy of the Ginkgo special extract EGb761 [®] within the framework of the mitochondrial cascade hypothesis of Alzheimer's disease. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 173-189.	2.6	45
243	CARBOHYDRATE-DEFICIENT TRANSFERRIN AS A SCREENING MARKER FOR DRINKING IN A GENERAL HOSPITAL POPULATION. <i>Alcohol and Alcoholism</i> , 1996, 31, 249-256.	1.6	44
244	A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. <i>Current Medical Research and Opinion</i> , 2005, 21, 1139-1146.	1.9	44
245	Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. <i>International Clinical Psychopharmacology</i> , 2010, 25, 204-213.	1.7	44
246	The Norepinephrine Transporter in Attention-Deficit/Hyperactivity Disorder Investigated With Positron Emission Tomography. <i>JAMA Psychiatry</i> , 2014, 71, 1340.	11.0	44
247	The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 4: Unmet Needs in the Treatment of Bipolar Disorder and Recommendations for Future Research. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, piiw072.	2.1	44
248	Making Sense of: Sensitization in Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 1-10.	2.1	44
249	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. <i>British Journal of Psychiatry</i> , 2019, 214, 36-41.	2.8	44
250	Risperidone for Tourette's syndrome. <i>Lancet, The</i> , 1994, 344, 1577-1578.	18.7	43
251	Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials. <i>Psychopharmacology</i> , 2002, 164, 301-308.	3.1	43
252	Gender differences in the psychopathology of depressed inpatients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 209-14.	3.2	43

#	ARTICLE	IF	CITATIONS
253	No association of clock gene T3111C polymorphism and affective disorders. <i>European Neuropsychopharmacology</i> , 2005, 15, 51-55.	0.7	43
254	Voxel-based morphometry at ultra-high fields. A comparison of 7T and 3T MRI data. <i>NeuroImage</i> , 2015, 113, 207-216.	4.2	43
255	Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study. <i>Translational Psychiatry</i> , 2019, 9, 64.	4.8	43
256	Escitalopram in the treatment of social anxiety disorder: Analysis of efficacy for different clinical subgroups and symptom dimensions. <i>Depression and Anxiety</i> , 2004, 20, 175-181.	4.1	42
257	Changing aspects of psychiatric inpatient treatment. <i>European Psychiatry</i> , 2004, 19, 483-488.	0.2	42
258	Meta-analysis: Fact or fiction? How to interpret meta-analyses. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 188-200.	2.6	42
259	International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets. <i>Pharmacological Reviews</i> , 2018, 70, 475-504.	16.0	42
260	PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. <i>Pharmacogenomics Journal</i> , 2014, 14, 463-472.	2.0	41
261	Drug-Induced Liver Injury during Antidepressant Treatment: Results of AMSP, a Drug Surveillance Program. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv126.	2.1	41
262	Seasonality in major depressed inpatients. <i>Journal of Affective Disorders</i> , 1990, 19, 243-248.	4.1	40
263	Antidepressant efficacy in relation to item analysis and severity of depression. <i>International Clinical Psychopharmacology</i> , 1995, 9, 3-12.	1.7	40
264	Circadian profiles of cortisol, prolactin, and thyrotropin in seasonal affective disorder. <i>Biological Psychiatry</i> , 1996, 39, 157-170.	1.3	40
265	Low Plasma Thyroid Indices of Depressed Patients are Attenuated by Antidepressant Drugs and Influence Treatment Outcome. <i>Pharmacopsychiatry</i> , 1996, 29, 180-186.	3.3	40
266	Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 364-375.	2.6	40
267	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 207-245.	3.2	40
268	Treatment of severe mania with intravenous magnesium sulphate as a supplementary therapy. <i>Psychiatry Research</i> , 1999, 89, 239-246.	3.3	39
269	Optimizing antidepressant treatment: are two actions better than one?. <i>International Clinical Psychopharmacology</i> , 2002, 17, 1.	1.7	39
270	Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. <i>European Psychiatry</i> , 2012, 27, 114-128.	0.2	39

#	ARTICLE	IF	CITATIONS
271	(S)-citalopram influences amygdala modulation in healthy subjects: a randomized placebo-controlled double-blind fMRI study using dynamic causal modeling. <i>NeuroImage</i> , 2015, 108, 243-250.	4.2	39
272	Stress management and the role of <i>Rhodiola rosea</i> : a review. <i>International Journal of Psychiatry in Clinical Practice</i> , 2018, 22, 242-252.	2.4	39
273	Machine learning classification of ADHD and HC by multimodal serotonergic data. <i>Translational Psychiatry</i> , 2020, 10, 104.	4.8	39
274	Safety and antidepressant efficacy of selective serotonin re-uptake inhibitors. <i>Human Psychopharmacology</i> , 1994, 9, 1-12.	1.5	38
275	Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression – A study with single photon emission computed tomography. <i>Psychiatry Research - Neuroimaging</i> , 1996, 68, 1-10.	1.8	38
276	Role of family history and 5-HTTLPR polymorphism in female seasonal affective disorder patients with and without premenstrual dysphoric disorder. <i>European Neuropsychopharmacology</i> , 2002, 12, 129-134.	0.7	38
277	C825T polymorphism in the G protein β 3-Subunit gene is associated with seasonal affective disorder. <i>Biological Psychiatry</i> , 2003, 54, 682-686.	1.3	38
278	The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder – A European Multicenter Study. <i>European Neuropsychopharmacology</i> , 2012, 22, 259-266.	0.7	38
279	Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 44, 271-278.	4.8	38
280	Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression. <i>Journal of Affective Disorders</i> , 2015, 184, 51-59.	4.1	38
281	The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 230-256.	2.1	38
282	Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 1-15.	2.6	38
283	Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder. <i>European Neuropsychopharmacology</i> , 2003, 13, 129-134.	0.7	37
284	Recurrent brief depressive disorder reinvestigated: a community sample of adolescents and young adults. <i>Psychological Medicine</i> , 2003, 33, 407-418.	4.5	37
285	The serotonin transporter promoter repeat length polymorphism, seasonal affective disorder and seasonality. <i>Psychological Medicine</i> , 2003, 33, 785-792.	4.5	37
286	5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2010, 25, 228-231.	1.7	37
287	Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET. <i>Human Brain Mapping</i> , 2016, 37, 884-895.	3.6	37
288	Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 401-412.	4.5	37

#	ARTICLE	IF	CITATIONS
289	Definition of treatment-resistant depression – Asia Pacific perspectives. <i>Journal of Affective Disorders</i> , 2019, 245, 626-636.	4.1	37
290	Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 183-193.	3.2	37
291	Efficacy of Antidepressants in the Treatment of Severe Depression. <i>Journal of Clinical Psychopharmacology</i> , 1997, 17, 19S-28S.	1.4	37
292	Ketamine-dependent neuronal activation in healthy volunteers. <i>Brain Structure and Function</i> , 2017, 222, 1533-1542.	2.3	36
293	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 108, 110170.	4.8	36
294	International Consensus Group on Bipolar I Depression Treatment Guidelines. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 571-9.	2.2	36
295	Seasonal changes in mood and behavior: A cluster analytic approach. <i>Psychiatry Research</i> , 1989, 28, 227-239.	3.3	35
296	Quetiapine in the Treatment of Borderline Personality Disorder. <i>World Journal of Biological Psychiatry</i> , 2003, 4, 42-44.	2.6	35
297	Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. <i>Depression and Anxiety</i> , 2004, 20, 44-47.	4.1	35
298	Efficacy of escitalopram compared to citalopram: a meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 261-268.	2.1	35
299	A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. <i>CNS Spectrums</i> , 2013, 18, 163-170.	1.2	35
300	Inverse Relation Between Stimulus Intensity and Seizure Duration: Implications for ECT Procedure. <i>Journal of ECT</i> , 2001, 17, 102-108.	0.6	34
301	A comparison of the Major Depression Inventory (MDI) and the Beck Depression Inventory (BDI) in severely depressed patients. <i>International Journal of Psychiatry in Clinical Practice</i> , 2011, 15, 56-61.	2.4	34
302	Imaging treatment effects in depression. <i>Reviews in the Neurosciences</i> , 2012, 23, 227-52.	2.9	34
303	RESCALE: Voxel-specific task-fMRI scaling using resting state fluctuation amplitude. <i>NeuroImage</i> , 2013, 70, 80-88.	4.2	34
304	Neuronal cell adhesion genes and antidepressant response in three independent samples. <i>Pharmacogenomics Journal</i> , 2015, 15, 538-548.	2.0	34
305	Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity. <i>Brain Structure and Function</i> , 2018, 223, 1369-1378.	2.3	34
306	Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 814-821.	2.1	34

#	ARTICLE	IF	CITATIONS
307	Pramipexole as adjunct to haloperidol in schizophrenia. <i>European Neuropsychopharmacology</i> , 1997, 7, 65-70.	0.7	33
308	Changes of clinical pattern in seasonal affective disorder (SAD) over time in a German-speaking sample. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2002, 252, 54-62.	3.2	33
309	Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. <i>Current Medical Research and Opinion</i> , 2004, 20, 869-878.	1.9	33
310	Hippocampal GABA levels correlate with retrieval performance in an associative learning paradigm. <i>NeuroImage</i> , 2020, 204, 116244.	4.2	33
311	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. <i>Translational Psychiatry</i> , 2020, 10, 50.	4.8	33
312	Hypericum in the Treatment of Seasonal Affective Disorders. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1994, 7, 29-33.	2.3	32
313	Gender-specific symptoms of depression and anger attacks. <i>The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender</i> , 2006, 3, 19-24.	0.2	32
314	Efficacy of St. John's wort extract WSÂ® 5570 in acute treatment of mild depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 258, 59-63.	3.2	32
315	Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET. <i>NeuroImage</i> , 2008, 41, 204-211.	4.2	32
316	COMT and age at onset in mood disorders: A replication and extension study. <i>Neuroscience Letters</i> , 2011, 498, 218-221.	2.1	32
317	Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 449-457.	2.1	32
318	Psychiatric patients' perception of physical restraint. <i>Acta Psychiatrica Scandinavica</i> , 2016, 133, 221-231.	4.5	32
319	Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 283-291.	8.8	32
320	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 330-348.	2.6	32
321	Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2018, 227, 777-786.	4.1	32
322	Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 560-573.	2.1	32
323	The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 93-104.	2.1	32
324	Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109835.	4.8	32

#	ARTICLE	IF	CITATIONS
325	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 483-494.	2.6	32
326	Anticipation in schizophrenia. <i>Schizophrenia Research</i> , 1999, 35, 25-32.	2.0	31
327	Reboxetine in the treatment of bulimia nervosa: a report of seven cases. <i>International Clinical Psychopharmacology</i> , 2000, 15, 351-356.	1.7	31
328	Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 685-695.	2.1	31
329	Oppositional COMT Val158Met effects on resting state functional connectivity in adolescents and adults. <i>Brain Structure and Function</i> , 2016, 221, 103-114.	2.3	31
330	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 203-210.	4.8	31
331	Combining machine learning algorithms for prediction of antidepressant treatment response. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 36-49.	4.5	31
332	Identifying the Common Genetic Basis of Antidepressant Response. <i>Biological Psychiatry Global Open Science</i> , 2022, 2, 115-126.	2.2	31
333	Multiple Hormone Responses to Stimulation with dl-Fenfluramine in Patients with Major Depression before and after Antidepressive Treatment. <i>Pharmacopsychiatry</i> , 1990, 23, 76-84.	3.3	30
334	Treatment of Seasonal Affective Disorder (SAD) with Hypericum Extract. <i>Pharmacopsychiatry</i> , 1997, 30, 89-93.	3.3	30
335	Reboxetine in seasonal affective disorder: an open trial. <i>European Neuropsychopharmacology</i> , 2001, 11, 1-5.	0.7	30
336	Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. <i>International Clinical Psychopharmacology</i> , 2001, 16, 179-187.	1.7	30
337	Cost-Effectiveness of Escitalopram versus Citalopram in the Treatment of Severe Depression. <i>Annals of Pharmacotherapy</i> , 2004, 38, 954-960.	1.9	30
338	Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol – A double-blind multicenter trial. <i>Journal of Psychiatric Research</i> , 2009, 43, 702-710.	3.1	30
339	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 406-428.	2.6	30
340	Bipolar II disorder as a risk factor for postpartum depression. <i>Journal of Affective Disorders</i> , 2016, 204, 54-58.	4.1	30
341	Effects of sex hormone treatment on white matter microstructure in individuals with gender dysphoria. <i>NeuroImage</i> , 2017, 150, 60-67.	4.2	30
342	Association of Protein Distribution and Gene Expression Revealed by PET and Post-Mortem Quantification in the Serotonergic System of the Human Brain. <i>Cerebral Cortex</i> , 2017, 27, 117-130.	2.9	30

#	ARTICLE	IF	CITATIONS
343	Acute and subsequent continuation electroconvulsive therapy elevates serum BDNF levels in patients with major depression. <i>Brain Stimulation</i> , 2019, 12, 1041-1050.	1.6	30
344	Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1997, 247, 291-296.	3.2	29
345	Bright light therapy in seasonal affective disorder – does it suffice?. <i>European Neuropsychopharmacology</i> , 2004, 14, 347-351.	0.7	29
346	The European Post-marketing Observational Sertindole Study: an investigation of the safety of antipsychotic drug treatment. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 59-68.	3.2	29
347	Phenomenology of psychotic mood disorders: Lifetime and major depressive episode features. <i>Journal of Affective Disorders</i> , 2011, 135, 241-250.	4.1	29
348	The genetic blueprint of major depressive disorder: Contributions of imaging genetics studies. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 474-488.	2.6	29
349	Epidemiology and socioeconomic impact of seasonal affective disorder in Austria. <i>European Psychiatry</i> , 2016, 32, 28-33.	0.2	29
350	Striatal dopaminergic alterations in Tourette’s syndrome: a meta-analysis based on 16 PET and SPECT neuroimaging studies. <i>Translational Psychiatry</i> , 2018, 8, 143.	4.8	29
351	Seasonality of Birth in Seasonal Affective Disorder. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1389-1393.	2.2	29
352	Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. <i>Psychiatry Research - Neuroimaging</i> , 1996, 68, 23-30.	1.8	28
353	Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. <i>European Neuropsychopharmacology</i> , 1997, 7, 115-124.	0.7	28
354	Different fatal toxicity of neuroleptics identified by autopsy. <i>European Neuropsychopharmacology</i> , 2001, 11, 117-124.	0.7	28
355	Escitalopram in Seasonal Affective Disorder: Results of an Open Trial. <i>Pharmacopsychiatry</i> , 2007, 40, 20-24.	3.3	28
356	Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder. <i>European Neuropsychopharmacology</i> , 2013, 23, 895-901.	0.7	28
357	Cerebral serotonin transporter asymmetry in females, males and male-to-female transsexuals measured by PET in vivo. <i>Brain Structure and Function</i> , 2014, 219, 171-183.	2.3	28
358	The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 1: Background and Methods of the Development of Guidelines. <i>International Journal of Neuropsychopharmacology</i> , 2016, 20, pyw091.	2.1	28
359	Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 681-697.	2.1	28
360	Life-long epigenetic programming of cortical architecture by maternal “Western” diet during pregnancy. <i>Molecular Psychiatry</i> , 2020, 25, 22-36.	7.9	28

#	ARTICLE	IF	CITATIONS
361	Psychotic Features in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	28
362	Efficacy of New Generation Antidepressants: Meta-Analysis of Imipramine-Controlled Studies. <i>Pharmacopsychiatry</i> , 1994, 27, 215-223.	3.3	27
363	Schizophrenia and the dopamine- β -hydroxylase gene. <i>Psychiatric Genetics</i> , 1996, 6, 17-22.	1.1	27
364	Quetiapine: efficacy and tolerability in schizophrenia. <i>European Neuropsychopharmacology</i> , 2001, 11, S405-S413.	0.7	27
365	Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study. <i>International Clinical Psychopharmacology</i> , 2001, 16, 189-196.	1.7	27
366	Acute Psychotropic Effects of Oral Cannabis Extract with a Defined Content of Δ^9 -Tetrahydrocannabinol (THC) in Healthy Volunteers. <i>Pharmacopsychiatry</i> , 2010, 43, 24-32.	3.3	27
367	Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 36-44.	2.6	27
368	Serotonin-1A receptor binding is positively associated with gray matter volume – A multimodal neuroimaging study combining PET and structural MRI. <i>NeuroImage</i> , 2012, 63, 1091-1098.	4.2	27
369	Temperament and character influence on depression treatment outcome. <i>Journal of Affective Disorders</i> , 2019, 252, 464-474.	4.1	27
370	Phototherapy in Subsyndromal Seasonal Affective Disorder (S-SAD) and "Diagnosed" Controls. <i>Pharmacopsychiatry</i> , 1988, 21, 428-429.	3.3	26
371	Seasonal affective disorder and the G-protein β -3-subunit C825T polymorphism. <i>Biological Psychiatry</i> , 2004, 55, 317-319.	1.3	26
372	Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2004, 19, 281-289.	1.7	26
373	Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases. <i>European Neuropsychopharmacology</i> , 2015, 25, 2183-2184.	0.7	26
374	Comparison of continuously acquired resting state and extracted analogues from active tasks. <i>Human Brain Mapping</i> , 2015, 36, 4053-4063.	3.6	26
375	A new nomenclature for classifying psychotropic drugs. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1614-1616.	2.4	26
376	Prediction of Autopsy Verified Neuropathological Change of Alzheimer's Disease Using Machine Learning and MRI. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 406.	3.4	26
377	WFSBP guidelines on how to grade treatment evidence for clinical guideline development. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 2-16.	2.6	26
378	A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2020, 35, 137-146.	1.7	26

#	ARTICLE	IF	CITATIONS
379	Thyroid hormones, body temperature, and antidepressant treatment. <i>Biological Psychiatry</i> , 1992, 31, 859-862.	1.3	25
380	Recurrent brief depression and its relationship to seasonal affective disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1992, 242, 20-26.	3.2	25
381	Biophotons, microtubules and CNS, is our brain a "Holographic computer"? <i>Medical Hypotheses</i> , 2004, 62, 169-172.	1.5	25
382	Milnacipran: a unique antidepressant?. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 23.	2.2	25
383	The efficacy of agomelatine in previously-treated depressed patients. <i>European Neuropsychopharmacology</i> , 2013, 23, 814-821.	0.7	25
384	Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials. <i>Wiener Medizinische Wochenschrift</i> , 2015, 165, 217-228.	1.1	25
385	Bipolar and related disorders in DSM-5 and ICD-10. <i>CNS Spectrums</i> , 2016, 21, 318-323.	1.2	25
386	On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study. <i>Translational Psychiatry</i> , 2020, 10, 2.	4.8	25
387	Meta-analysis of brain structural changes after electroconvulsive therapy in depression. <i>Brain Stimulation</i> , 2021, 14, 927-937.	1.6	25
388	A Longitudinal View of Triggers and Thresholds of Suicidal Behavior in Depression. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 866-873.	2.2	25
389	Social phobia: the nature of the disorder. <i>Journal of Affective Disorders</i> , 1998, 50, S3-S9.	4.1	24
390	Milnacipran in the treatment of bulimia nervosa: a report of 16 cases. <i>European Neuropsychopharmacology</i> , 2003, 13, 73-79.	0.7	24
391	Treatment of Seasonal Affective Disorder with Duloxetine: An Open-Label Study. <i>Pharmacopsychiatry</i> , 2008, 41, 100-105.	3.3	24
392	Superiority of escitalopram to paroxetine in the treatment of depression. <i>European Neuropsychopharmacology</i> , 2009, 19, 229-237.	0.7	24
393	Is Dopamine Neurotransmission Altered in Prodromal Schizophrenia? A Review of the Evidence. <i>Current Pharmaceutical Design</i> , 2012, 18, 1568-1579.	1.9	24
394	Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 93-103.	3.2	24
395	Influence of Sex on Suicidal Phenotypes in Affective Disorder Patients with Traumatic Childhood Experiences. <i>PLoS ONE</i> , 2015, 10, e0137763.	2.5	24
396	Dose escalation of antipsychotic drugs in schizophrenia: A meta-analysis of randomized controlled trials. <i>Schizophrenia Research</i> , 2015, 166, 187-193.	2.0	24

#	ARTICLE	IF	CITATIONS
397	Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015, 19, 158-167.	2.4	24
398	Paternal and maternal age as risk factors for schizophrenia: a case-control study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2018, 22, 170-176.	2.4	24
399	Effects of testosterone treatment on hypothalamic neuroplasticity in female-to-male transgender individuals. <i>Brain Structure and Function</i> , 2018, 223, 321-328.	2.3	24
400	The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. <i>Brain Stimulation</i> , 2019, 12, 714-723.	1.6	24
401	Trazodone and Amitriptyline in Treatment of Depressed Inpatients. <i>Pharmacopsychiatry</i> , 1981, 14, 167-171.	3.3	23
402	D2-Dopamine Receptor Occupancy measured by IBZM-SPECT in Relation to Extrapyramidal Side Effects. <i>Pharmacopsychiatry</i> , 1998, 31, 159-162.	3.3	23
403	Enlarged Cerebrospinal Fluid Spaces in Opiate-Dependent Male Patients: A Stereological CT Study. <i>Neuropsychobiology</i> , 1998, 38, 80-83.	1.9	23
404	Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance. <i>International Clinical Psychopharmacology</i> , 2000, 15, 207-214.	1.7	23
405	Depression and Anxiety-Separate or Continuum?. <i>World Journal of Biological Psychiatry</i> , 2001, 2, 162-163.	2.6	23
406	Intravenous antidepressant treatment: focus on citalopram. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2002, 252, 105-109.	3.2	23
407	2-COM: an instrument to facilitate patient-professional communication in routine clinical practice. <i>Acta Psychiatrica Scandinavica</i> , 2002, 106, 446-452.	4.5	23
408	Tardive dyskinesia: Analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. <i>Schizophrenia Research</i> , 2006, 81, 139-143.	2.0	23
409	Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [carbonyl-11C]WAY-100635. <i>Psychoneuroendocrinology</i> , 2014, 45, 1-10.	2.7	23
410	World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015, 19, 2-7.	2.4	23
411	Venous thromboembolism during treatment with antipsychotics: Results of a drug surveillance programme. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 175-186.	2.6	23
412	The pulvinar nucleus and antidepressant treatment: dynamic modeling of antidepressant response and remission with ultra-high field functional MRI. <i>Molecular Psychiatry</i> , 2019, 24, 746-756.	7.9	23
413	Sex Matters: A Multivariate Pattern Analysis of Sex- and Gender-Related Neuroanatomical Differences in Cis- and Transgender Individuals Using Structural Magnetic Resonance Imaging. <i>Cerebral Cortex</i> , 2020, 30, 1345-1356.	2.9	23
414	Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 440-445.	2.1	23

#	ARTICLE	IF	CITATIONS
415	Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivityâ€“impulsivity symptoms in ADHD measured with PET. <i>Molecular Psychiatry</i> , 2021, 26, 1009-1018.	7.9	23
416	Comments on "Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders" by Tran and Associates. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 353-354.	1.4	23
417	Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999, 249, S1-S14.	3.2	22
418	Recurrent brief depression revisited. <i>International Review of Psychiatry</i> , 2005, 17, 63-70.	2.8	22
419	How to grade categories of evidence. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 242-247.	2.6	22
420	Failure to Replicate Influence of GRIK4 and GNB3 Polymorphisms on Treatment Outcome in Major Depression. <i>Neuropsychobiology</i> , 2012, 65, 70-75.	1.9	22
421	The influence of the rs6295 gene polymorphism on serotonin-1A receptor distribution investigated with PET in patients with major depression applying machine learning. <i>Translational Psychiatry</i> , 2017, 7, e1150-e1150.	4.8	22
422	Imaging the neuroplastic effects of ketamine with VBM and the necessity of placebo control. <i>NeuroImage</i> , 2017, 147, 198-203.	4.2	22
423	Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 145-153.	2.1	22
424	Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. <i>Translational Psychiatry</i> , 2018, 8, 198.	4.8	22
425	Hippocampal Subfields in Acute and Remitted Depressionâ€“an Ultra-High Field Magnetic Resonance Imaging Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 513-522.	2.1	22
426	Making Sense of Connectivity. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 194-207.	2.1	22
427	Low platelet MAO activity and schizophrenia: sex differences. <i>Acta Psychiatrica Scandinavica</i> , 1981, 64, 167-174.	4.5	21
428	Mirtazapine in recurrent brief depression. <i>International Clinical Psychopharmacology</i> , 1998, 13, 39-40.	1.7	21
429	Mirtazapine in seasonal affective disorder (SAD): a preliminary report. <i>Human Psychopharmacology</i> , 1999, 14, 59-62.	1.5	21
430	Fluoxetine treatment in patients with recurrent brief depression. <i>International Clinical Psychopharmacology</i> , 2001, 16, 221-226.	1.7	21
431	Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression. <i>Neuroscience Letters</i> , 2012, 516, 85-88.	2.1	21
432	Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 13-22.	3.2	21

#	ARTICLE	IF	CITATIONS
433	Gender transition affects neural correlates of empathy: A resting state functional connectivity study with ultra high-field 7T MR imaging. <i>NeuroImage</i> , 2016, 138, 257-265.	4.2	21
434	Meta-analysis of the COMT Val158Met polymorphism in major depressive disorder: the role of gender. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 147-158.	2.6	21
435	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 723-735.	3.2	21
436	Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET. <i>Human Brain Mapping</i> , 2017, 38, 792-802.	3.6	21
437	Prognosis and Improved Outcomes in Major Depression: A Review. <i>Focus (American Psychiatric Association)</i> , 2017, 15, 100-108.	0.8	21
438	Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 104, 110050.	4.8	21
439	Risk of suicide in depression and its implication for psychopharmacological treatment. <i>International Clinical Psychopharmacology</i> , 1996, 11, 71-9.	1.7	21
440	Auditory evoked potentials and total sleep deprivation in depressed patients. <i>Psychiatry Research</i> , 1988, 25, 91-100.	3.3	20
441	Efficacy, safety, and indications for tricyclic and newer antidepressants. <i>Depression</i> , 1994, 2, 127-137.	0.6	20
442	Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine. <i>Psychopharmacology</i> , 1997, 133, 102-105.	3.1	20
443	Escitalopram in the Long-Term Treatment of Major Depressive Disorder in Elderly Patients. <i>Neuropsychobiology</i> , 2006, 54, 152-159.	1.9	20
444	Polymorphisms of the 5-HT _{2A} Receptor Gene and Clinical Response to Olanzapine in Paranoid Schizophrenia. <i>Neuropsychobiology</i> , 2011, 64, 202-210.	1.9	20
445	Actigraphy in patients with treatment-resistant depression undergoing electroconvulsive therapy. <i>Journal of Psychiatric Research</i> , 2014, 57, 96-100.	3.1	20
446	Anti-Oxidative Effects of Melatonin Receptor Agonist and Omega-3 Polyunsaturated Fatty Acids in Neuronal SH-SY5Y Cells: Deciphering Synergic Effects on Anti-Depressant Mechanisms. <i>Molecular Neurobiology</i> , 2018, 55, 7271-7284.	4.0	20
447	Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 94, 109638.	4.8	20
448	Tissue-specific regulation of vasoactive intestinal peptide messenger ribonucleic acid levels by estrogen in the rat. <i>Endocrinology</i> , 1992, 130, 1796-1801.	2.8	19
449	Use of light therapy in German psychiatric hospitals. <i>European Psychiatry</i> , 1994, 9, 288-292.	0.2	19
450	Editorial. <i>Pharmacopsychiatry</i> , 1997, 30, 71-71.	3.3	19

#	ARTICLE	IF	CITATIONS
451	Prevalence and Distribution of Hepatitis C Subtypes in Patients with Opioid Dependence. <i>European Addiction Research</i> , 2000, 6, 198-204.	2.4	19
452	In vivo 123I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients. <i>Psychopharmacology</i> , 2001, 157, 236-242.	3.1	19
453	Issues in the treatment of bipolar disorder. <i>European Neuropsychopharmacology</i> , 2003, 13, 37-42.	0.7	19
454	Placebo-controlled trials in major depression are necessary and ethically justifiable. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 258-260.	3.2	19
455	Optimisation of long-term treatment in schizophrenia: Treating the true spectrum of symptoms. <i>European Neuropsychopharmacology</i> , 2006, 16, S135-S141.	0.7	19
456	Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl-11C]WAY-100635 independent of arterial sampling. <i>NeuroImage</i> , 2012, 62, 199-206.	4.2	19
457	Neuropsychiatric deep brain stimulation for translational neuroimaging. <i>NeuroImage</i> , 2013, 79, 30-41.	4.2	19
458	Relation of progesterone and DHEAS serum levels to 5-HT1A receptor binding potential in pre- and postmenopausal women. <i>Psychoneuroendocrinology</i> , 2014, 46, 52-63.	2.7	19
459	The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment – a European multicentre study. <i>International Clinical Psychopharmacology</i> , 2016, 31, 1-7.	1.7	19
460	Simple and rapid quantification of serotonin transporter binding using [11C]DASB bolus plus constant infusion. <i>NeuroImage</i> , 2017, 149, 23-32.	4.2	19
461	The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes – Results from a cross-sectional European multicenter study. <i>European Neuropsychopharmacology</i> , 2017, 27, 625-632.	0.7	19
462	Repetitive enhancement of serum <sc>BDNF</sc> subsequent to continuation <sc>ECT</sc>. <i>Acta Psychiatrica Scandinavica</i> , 2019, 140, 426-434.	4.5	19
463	Cardiovascular Adverse Reactions During Antipsychotic Treatment: Results of AMSP, A Drug Surveillance Program Between 1993 and 2013. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 67-75.	2.1	19
464	Reconceptualising treatment-resistant depression as difficult-to-treat depression. <i>Lancet Psychiatry</i> , 2021, 8, 14-15.	7.4	19
465	Plant-based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-review of Meta-analyses of Randomized Controlled Trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses d'essais randomisés contrôlés. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 849-862.	1.9	19
466	Silexan in generalized anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2017, 32, 195-204.	1.7	19
467	Platelet Serotonin Transporter Function Predicts Default-Mode Network Activity. <i>PLoS ONE</i> , 2014, 9, e92543.	2.5	19
468	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. <i>European Neuropsychopharmacology</i> , 2022, 55, 86-95.	0.7	19

#	ARTICLE	IF	CITATIONS
469	Immunological correlates of seasonal fluctuations in mood and behavior and their relationship to phototherapy. <i>Psychiatry Research</i> , 1991, 36, 253-264.	3.3	18
470	A Controlled Study of the Efficacy and Safety of Mianserin and Amitriptyline in Depressive Inpatients. <i>Pharmacopsychiatry</i> , 1995, 28, 249-252.	3.3	18
471	Striatal D2 receptor occupancy in bipolar patients treated with olanzapine. <i>European Neuropsychopharmacology</i> , 2007, 17, 102-107.	0.7	18
472	Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: Results of a multi-centre observational trial. <i>European Psychiatry</i> , 2007, 22, 195-202.	0.2	18
473	Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: A pooled analysis. <i>Journal of Psychiatric Research</i> , 2009, 43, 792-797.	3.1	18
474	Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. <i>International Clinical Psychopharmacology</i> , 2010, 25, 297-301.	1.7	18
475	Progesterone Level Predicts Serotonin-1A Receptor Binding in the Male Human Brain. <i>Neuroendocrinology</i> , 2011, 94, 84-88.	2.5	18
476	Comorbid hypertension in patients with major depressive disorder – Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2019, 29, 777-785.	0.7	18
477	Reliability of task-specific neuronal activation assessed with functional PET, ASL and BOLD imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2986-2999.	4.3	18
478	Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. <i>Depression and Anxiety</i> , 2021, 38, 896-906.	4.1	18
479	Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1999, 291, 547-54.	2.5	18
480	Poststroke depression and fluoxetine. <i>American Journal of Psychiatry</i> , 1996, 153, 446b-447.	7.2	17
481	Tryptophan depletion. <i>International Clinical Psychopharmacology</i> , 1999, 14, 313-316.	1.7	17
482	Occurrence of mirtazapine-induced delirium in organic brain disorder. <i>International Clinical Psychopharmacology</i> , 2000, 15, 239-244.	1.7	17
483	Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin. <i>European Neuropsychopharmacology</i> , 2002, 12, 119-122.	0.7	17
484	Effects of tryptophan depletion and catecholamine depletion on immune parameters in patients with seasonal affective disorder in remission with light therapy. <i>Biological Psychiatry</i> , 2003, 53, 332-337.	1.3	17
485	Possible linkage of schizophrenia and bipolar affective disorder to chromosome 3q29. <i>Journal of Psychiatric Research</i> , 2004, 38, 357-364.	3.1	17
486	Serotonin transporter promoter gene polymorphic region (5-HTTLPR) and personality in female patients with seasonal affective disorder and in healthy controls. <i>European Neuropsychopharmacology</i> , 2004, 14, 53-58.	0.7	17

#	ARTICLE	IF	CITATIONS
487	Therapy of Treatment Resistant Depression: Focus on the Management of TRD with Atypical Antipsychotics. <i>CNS Spectrums</i> , 2004, 9, 823-832.	1.2	17
488	Trazodone-induced cardiac arrhythmias: a report of two cases. <i>Human Psychopharmacology</i> , 2006, 21, 61-62.	1.5	17
489	Actigraphic Measurements in Opioid Detoxification With Methadone or Buprenorphine. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 75-82.	1.4	17
490	On the application of light therapy in German-speaking countries. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 501-505.	3.2	17
491	Melancholic features in major depression – a European multicenter study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110285.	4.8	17
492	Do SSRIs differ in their antidepressant efficacy. <i>Human Psychopharmacology</i> , 1995, 10, S163-S172.	1.5	16
493	The media and intellectuals' response to medical publications: the anti-depressants' case. <i>Annals of General Psychiatry</i> , 2013, 12, 11.	2.7	16
494	The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk – a European multicentre study on treatment-resistant major depressive disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 385-391.	3.2	16
495	A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities. <i>European Neuropsychopharmacology</i> , 2014, 24, 1463-1474.	0.7	16
496	Individual Diversity of Functional Brain Network Economy. <i>Brain Connectivity</i> , 2015, 5, 156-165.	1.7	16
497	Neuroscience-based Nomenclature (NbN): A call for action. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 318-320.	2.6	16
498	Multicenter, open-label, exploratory clinical trial with “Rhodiola rosea“ extract in patients suffering from burnout symptoms. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 889-898.	2.2	16
499	DiGeorge syndrome. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 283-287.	1.9	16
500	Changes in White Matter Microstructure After Electroconvulsive Therapy for Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 20-25.	2.1	16
501	Therapeutic sleep deprivation and antidepressant medication in patients with major depression. <i>European Neuropsychopharmacology</i> , 1991, 1, 107-111.	0.7	15
502	Paranoid delusions and hallucinations and bright light therapy in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 1071-1072.	2.7	15
503	Pharmacotherapy of Seasonal Affective Disorder. <i>CNS Spectrums</i> , 2005, 10, 664-669.	1.2	15
504	Addressing the limitations of the CATIE study. <i>World Journal of Biological Psychiatry</i> , 2006, 7, 126-127.	2.6	15

#	ARTICLE	IF	CITATIONS
505	Quetiapine in combination with citalopram in patients with unipolar psychotic depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 242-247.	4.8	15
506	Hypothalamic serotonin-1A receptor binding measured by PET predicts the plasma level of dehydroepiandrosterone sulfate in healthy women. <i>Neuroscience Letters</i> , 2010, 476, 161-165.	2.1	15
507	What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 472-482.	2.6	15
508	Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression – Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2018, 28, 1305-1313.	0.7	15
509	Cutaneous adverse drug reactions to psychotropic drugs and their risk factors – a case-control study. <i>European Neuropsychopharmacology</i> , 2019, 29, 111-121.	0.7	15
510	The Influence of Acute SSRI Administration on White Matter Microstructure in Patients Suffering From Major Depressive Disorder and Healthy Controls. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 542-550.	2.1	15
511	Translating the immediate effects of S-Ketamine using hippocampal subfield analysis in healthy subjects-results of a randomized controlled trial. <i>Translational Psychiatry</i> , 2021, 11, 200.	4.8	15
512	Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 48-52.	2.0	15
513	Maintenance ECT for treatment of therapy-resistant paranoid schizophrenia and Parkinson's disease. <i>Biological Psychiatry</i> , 1995, 37, 892-894.	1.3	14
514	Association study of schizophrenia spectrum disorders and dopamine D3 receptor gene: is schizoaffective disorder special?. <i>Psychiatry Research</i> , 2000, 96, 179-183.	3.3	14
515	The Korean Medication Algorithm for Major Depressive Disorder (KMA-MDD): Report of the Korean Society of Depressive and Bipolar Disorders. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006, 10, 186-194.	2.4	14
516	Interaction between serotonin 5-HT2A receptor gene and dopamine transporter (DAT1) gene polymorphisms influences personality trait of persistence in Austrian Caucasians. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 417-424.	2.6	14
517	Psychosocial background in incarcerated adolescents from Austria, Turkey and former Yugoslavia. <i>Psychiatry Research</i> , 2011, 185, 193-199.	3.3	14
518	Improvement of the noradrenergic symptom cluster following treatment with milnacipran. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 21.	2.2	14
519	A highly parallelized framework for computationally intensive MR data analysis. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2012, 25, 313-320.	2.0	14
520	Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients. <i>Journal of Affective Disorders</i> , 2013, 150, 649-652.	4.1	14
521	Factors contributing to the increasing placebo response in antidepressant trials. <i>World Psychiatry</i> , 2015, 14, 304-306.	10.4	14
522	Manifesto for an international digital mental health network. <i>Digital Psychiatry</i> , 2019, 2, 14-24.	2.1	14

#	ARTICLE	IF	CITATIONS
523	Extrapyramidal reactions following treatment with antidepressants: Results of the AMSP multinational drug surveillance programme. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 308-316.	2.6	14
524	Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2020, 41, 70-80.	0.7	14
525	Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. <i>Journal of Psychiatric Research</i> , 2021, 141, 167-175.	3.1	14
526	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 715-727.	3.2	14
527	The importance of treatment acceptability to patients. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000, 4, 25-34.	2.4	13
528	ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder. <i>European Neuropsychopharmacology</i> , 2004, 14, 425-433.	0.7	13
529	Impact of COMT genotype on serotonin-1A receptor binding investigated with PET. <i>Brain Structure and Function</i> , 2014, 219, 2017-2028.	2.3	13
530	A proposal for a psychopharmacology – pharmacotherapy catalogue of learning objectives and a curriculum in Europe. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 29-38.	2.6	13
531	Has the existence of seasonal affective disorder been disproven?. <i>Journal of Affective Disorders</i> , 2017, 208, 54-55.	4.1	13
532	Association between dynamic resting-state functional connectivity and ketamine plasma levels in visual processing networks. <i>Scientific Reports</i> , 2019, 9, 11484.	3.3	13
533	The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. <i>CNS Spectrums</i> , 2021, 26, 562-586.	1.2	13
534	Topiramate as a mood stabilizer. <i>International Clinical Psychopharmacology</i> , 2001, 16, 295-298.	1.7	12
535	Successful Treatment of Recurrent Brief Depression with Reboxetine - A Single Case Analysis. <i>Pharmacopsychiatry</i> , 2002, 35, 75-76.	3.3	12
536	Maintenance treatment in depression: the role of pharmacological and psychological treatment. <i>Current Opinion in Psychiatry</i> , 2002, 15, 63-68.	6.3	12
537	Intravenous mirtazapine in the treatment of depressed inpatients. <i>European Neuropsychopharmacology</i> , 2002, 12, 57-60.	0.7	12
538	Anger attacks in seasonal affective disorder. <i>International Journal of Neuropsychopharmacology</i> , 2006, 9, 215.	2.1	12
539	Ranking antidepressants. <i>Lancet, The</i> , 2009, 373, 1760-1761.	13.7	12
540	Intensive care in psychiatry. <i>European Psychiatry</i> , 2011, 26, 260-264.	0.2	12

#	ARTICLE	IF	CITATIONS
541	Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study. <i>International Journal of Bipolar Disorders</i> , 2014, 2, 13.	2.2	12
542	Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding. <i>NeuroImage</i> , 2015, 111, 505-512.	4.2	12
543	The Impact of COMT and Childhood Maltreatment on Suicidal Behaviour in Affective Disorders. <i>Scientific Reports</i> , 2018, 8, 692.	3.3	12
544	Parcellation of the Human Cerebral Cortex Based on Molecular Targets in the Serotonin System Quantified by Positron Emission Tomography In vivo. <i>Cerebral Cortex</i> , 2019, 29, 372-382.	2.9	12
545	Schlafentzugtherapie – eine Chance bei Antidepressiva-Nonresponse?. , 1990, , 149-166.		12
546	Adverse effects of δ^9 -tetrahydrocannabinol on neuronal bioenergetics during postnatal development. <i>JCI Insight</i> , 2020, 5, .	5.0	12
547	Serotonergically induced hormonal responses and the antidepressant effect of total sleep deprivation in patients with major depression. <i>Psychopharmacology Bulletin</i> , 1988, 24, 450-3.	0.0	12
548	Algorithms for the treatment of subtypes of unipolar major depression. <i>Psychopharmacology Bulletin</i> , 1995, 31, 475-82.	0.0	12
549	Early clinical results with the neuroleptic roxindole (EMD 49 980) in the treatment of schizophrenia – an open study. <i>European Neuropsychopharmacology</i> , 1992, 2, 91-95.	0.7	11
550	How much do novel antipsychotics benefit the patients?. <i>International Clinical Psychopharmacology</i> , 1998, 13, S71-S78.	1.7	11
551	Weak antidepressant response after bupropion augmentation of serotonin reuptake inhibitors in refractory severe depression. <i>International Clinical Psychopharmacology</i> , 1998, 13, 83-86.	1.7	11
552	Menstrual disturbances – a rare side-effect of bright-light therapy. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 239-240.	2.1	11
553	Validation of a Simplified Definition of Anger Attacks. <i>Psychotherapy and Psychosomatics</i> , 2006, 75, 103-106.	8.8	11
554	Humoral phototransduction: Light transportation in the blood, and possible biological effects. <i>Medical Hypotheses</i> , 2008, 71, 314-317.	1.5	11
555	Silexan does not cause withdrawal symptoms even when abruptly discontinued. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 177-180.	2.4	11
556	Evidence for the Efficacy of Bright Light Therapy for Bipolar Depression. <i>American Journal of Psychiatry</i> , 2018, 175, 905-906.	7.2	11
557	Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging. <i>European Neuropsychopharmacology</i> , 2019, 29, 711-719.	0.7	11
558	Predicting Antidepressant Citalopram Treatment Response via Changes in Brain Functional Connectivity After Acute Intravenous Challenge. <i>Frontiers in Computational Neuroscience</i> , 2020, 14, 554186.	2.1	11

#	ARTICLE	IF	CITATIONS
559	Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DRD2/3 gene expression in the human brain. <i>NeuroImage</i> , 2020, 223, 117270.	4.2	11
560	Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta-analysis. <i>Brain and Behavior</i> , 2021, 11, e01997.	2.2	11
561	Jahreszeit und Befindlichkeit in der Allgemeinbevölkerung. <i>Monographien Aus Dem Gesamtgebiete Der Psychiatrie</i> , 1991, , .	0.1	11
562	Exploring the Impact of BDNF Val66Met Genotype on Serotonin Transporter and Serotonin-1A Receptor Binding. <i>PLoS ONE</i> , 2014, 9, e106810.	2.5	11
563	Social anxiety disorder: epidemiology, biology and treatment. <i>Psychiatria Danubina</i> , 2009, 21, 533-42.	0.4	11
564	Trigeminal neuralgic syndrome after bright light therapy. <i>American Journal of Psychiatry</i> , 1995, 152, 1237-1237.	7.2	10
565	New aspects of diagnosis and pharmacotherapy of eating disorders. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997, 1, 21-35.	2.4	10
566	Sertindole: safety and tolerability profile. <i>International Journal of Psychiatry in Clinical Practice</i> , 2002, 6, 27-32.	2.4	10
567	Intravenous Mirtazapine Is Safe and Effective in the Treatment of Depressed Inpatients. <i>Neuropsychobiology</i> , 2006, 53, 83-87.	1.9	10
568	Placebo controlled continuation treatment with Hypericum extract WSÂ® 5570 after recovery from a mild or moderate depressive episode. <i>Wiener Medizinische Wochenschrift</i> , 2007, 157, 362-366.	1.1	10
569	The psychiatrist confronted with a fibromyalgia patient. <i>Human Psychopharmacology</i> , 2009, 24, S25-30.	1.5	10
570	No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression. <i>Psychiatry Research</i> , 2011, 188, 166-169.	3.3	10
571	Impact of electroconvulsive therapy on 5-HT1A receptor binding in major depression. <i>Molecular Psychiatry</i> , 2013, 18, 1-1.	7.9	10
572	The Impact of Adverse Life Events on Clinical Features and Interaction with Gene Variants in Mood Disorder Patients. <i>Psychopathology</i> , 2013, 46, 384-389.	1.5	10
573	Increasing placebo response in antipsychotic trials: a clinical perspective. <i>Evidence-Based Mental Health</i> , 2015, 18, 77-79.	4.5	10
574	The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 782-787.	2.1	10
575	Prevention of seasonal affective disorder in daily clinical practice: results of a survey in German-speaking countries. <i>BMC Psychiatry</i> , 2017, 17, 247.	2.6	10
576	Implementing prevention of seasonal affective disorder from patientsâ€™ and physiciansâ€™ perspectives â€“ a qualitative study. <i>BMC Psychiatry</i> , 2018, 18, 372.	2.6	10

#	ARTICLE	IF	CITATIONS
577	Topologically Guided Prioritization of Candidate Gene Transcripts Coexpressed with the 5-HT1A Receptor by Combining In Vivo PET and Allen Human Brain Atlas Data. <i>Cerebral Cortex</i> , 2020, 30, 3771-3780.	2.9	10
578	Personality as a dimension of summer and winter depression. <i>Psychopharmacology Bulletin</i> , 1988, 24, 476-83.	0.0	10
579	Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1995, 33, 646-52.	0.6	10
580	First-episode schizophrenia: the importance of early intervention and subjective tolerability. <i>Journal of Clinical Psychiatry</i> , 1999, 60 Suppl 23, 5-9.	2.2	10
581	Clinical Response to Sleep Deprivation and Auditory-Evoked Potentials - Preliminary Results. <i>Pharmacopsychiatry</i> , 1994, 27, 70-71.	3.3	9
582	Seasonal affective disorder in a tropical country: a case report. <i>Psychiatry Research</i> , 1995, 56, 11-15.	3.3	9
583	Recurrent Brief Depression. <i>CNS Drugs</i> , 1995, 4, 222-229.	5.9	9
584	The Place of Milnacipran in the Treatment of Depression. <i>Human Psychopharmacology</i> , 1997, 12, S135-S141.	1.5	9
585	Occurrence of trazodone-induced delirium. <i>International Clinical Psychopharmacology</i> , 1998, 13, 225-228.	1.7	9
586	Effect of intravenous magnesium sulphate in reducing irritability and restlessness in pure and polysubstance opiate detoxification. <i>Psychiatry Research</i> , 2005, 135, 53-63.	3.3	9
587	Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia. <i>International Clinical Psychopharmacology</i> , 2014, 29, 166-176.	1.7	9
588	Influence of CRHR1 Polymorphisms and Childhood Abuse on Suicide Attempts in Affective Disorders: A GxE Approach. <i>Frontiers in Psychiatry</i> , 2018, 9, 165.	2.6	9
589	Alcohol consumption in Austrian physicians. <i>Annals of General Psychiatry</i> , 2019, 18, 22.	2.7	9
590	Seasonality of antidepressant prescriptions and sick leaves. <i>Journal of Psychiatric Research</i> , 2019, 111, 128-133.	3.1	9
591	Genetic variants associated with psychotic symptoms across psychiatric disorders. <i>Neuroscience Letters</i> , 2020, 720, 134754.	2.1	9
592	Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts. <i>International Clinical Psychopharmacology</i> , 2022, 37, 38-45.	1.7	9
593	Evidence for a seasonal form of recurrent brief depression (RBD-seasonal). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1994, 244, 205-210.	3.2	8
594	Treatment of unipolar major depression: Algorithms for pharmacotherapy. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997, 1, S5-S7.	2.4	8

#	ARTICLE	IF	CITATIONS
595	Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study. <i>Psychopharmacology</i> , 2002, 159, 445-446.	3.1	8
596	A Cys23→Ser23 substitution in the 5-HT receptor gene influences body weight regulation in females with seasonal affective disorder: An Austrian→Canadian collaborative study. <i>Journal of Psychiatric Research</i> , 2005, 39, 561-567.	3.1	8
597	Binding kinetics of 123I[ADAM] in healthy controls: a selective SERT radioligand. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 211.	2.1	8
598	Additional support for linkage of schizophrenia and bipolar disorder to chromosome 3q29. <i>European Neuropsychopharmacology</i> , 2007, 17, 501-505.	0.7	8
599	Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria. <i>Human Psychopharmacology</i> , 2007, 22, 245-251.	1.5	8
600	Season of birth in siblings of patients with seasonal affective disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 378-382.	3.2	8
601	The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm". <i>International Journal of Psychiatry in Clinical Practice</i> , 2013, 17, 78-89.	2.4	8
602	How well do randomized controlled trial data generalize to "real-world" clinical practice settings? A comparison of two generalized anxiety disorder studies. <i>European Neuropsychopharmacology</i> , 2014, 24, 125-132.	0.7	8
603	Family history of major depression and residual symptoms in responder and non-responder depressed patients. <i>Comprehensive Psychiatry</i> , 2014, 55, 51-55.	3.1	8
604	Treatment of depressive symptoms in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2015, 30, 14-22.	1.7	8
605	High occupational level is associated with poor response to treatment of depression. <i>European Neuropsychopharmacology</i> , 2016, 26, 1320-1326.	0.7	8
606	Ketamine for the Treatment of Depression. <i>JAMA Psychiatry</i> , 2017, 74, 970.	11.0	8
607	A case-control study of paternal and maternal age as risk factors in mood disorders. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 90-98.	2.4	8
608	Editorial for Treatment-Resistant Depression (TRD). <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 83-84.	2.1	8
609	Opinion paper: poor response to treatment of depression in people in high occupational levels. <i>Psychological Medicine</i> , 2019, 49, 49-54.	4.5	8
610	Monoamine Depletion in Non-Pharmacological Treatments for Depression. <i>Advances in Experimental Medicine and Biology</i> , 1999, 467, 29-33.	1.6	8
611	Treatment of Patients With Delirium. <i>American Journal of Psychiatry</i> , 2000, 157, 1711-1711.	7.2	8
612	Polygenic risk scores for neuropsychiatric, inflammatory, and cardio→metabolic traits highlight possible genetic overlap with suicide attempt and treatment→emergent suicidal ideation. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2022, 189, 74-85.	1.7	8

#	ARTICLE	IF	CITATIONS
613	Subthreshold depression – concept, operationalisation and epidemiological data. A scoping review. <i>International Journal of Psychiatry in Clinical Practice</i> , 2023, 27, 92-106.	2.4	8
614	Zotepine in the treatment of acute hospitalized schizophrenic episodes. <i>International Clinical Psychopharmacology</i> , 2001, 16, 163-168.	1.7	7
615	Continuation and long-term maintenance treatment with Hypericum extract WSÂ® 5570 after successful acute treatment of mild to moderate depression – rationale and study design. <i>International Journal of Methods in Psychiatric Research</i> , 2004, 13, 176-183.	2.1	7
616	Unique mechanism of action for escitalopram: does it hold the promise?. <i>International Journal of Psychiatry in Clinical Practice</i> , 2004, 8, 15-18.	2.4	7
617	Serum lipid levels in seasonal affective disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 197-202.	3.2	7
618	Do we need another atypical antipsychotic?. <i>European Neuropsychopharmacology</i> , 2008, 18, S146-S152.	0.7	7
619	Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 715-725.	2.1	7
620	Clinical data in early intervention. <i>International Psychogeriatrics</i> , 2012, 24, S41-S45.	1.0	7
621	Treatment-resistant depression: a challenge for future research. <i>Acta Neuropsychiatrica</i> , 2014, 26, 131-133.	2.1	7
622	Association study of CREB1 polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression. <i>International Journal of Neuroscience</i> , 2015, 125, 336-343.	1.6	7
623	Use of Light Therapy by Office-Based Physicians. <i>Neuropsychobiology</i> , 2016, 74, 182-187.	1.9	7
624	The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: 5-HTTLPR and other variants. <i>Human Psychopharmacology</i> , 2018, 33, e2682.	1.5	7
625	Rapid antidepressant effect of S-ketamine in schizophrenia. <i>European Neuropsychopharmacology</i> , 2018, 28, 980-982.	0.7	7
626	Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression. <i>Translational Psychiatry</i> , 2019, 9, 5.	4.8	7
627	Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. <i>Journal of Affective Disorders</i> , 2021, 279, 722-729.	4.1	7
628	Editorial 1. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, 25, 1-1.	2.4	7
629	Paroxetine in a patient with obsessive-compulsive disorder, anorexia nervosa and schizotypal personality disorder. <i>Journal of Psychiatry and Neuroscience</i> , 1998, 23, 179-80.	2.4	7
630	Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 1998, 13, 253-62.	1.7	7

#	ARTICLE	IF	CITATIONS
631	Diagnosis and Treatment of Subsyndromal Seasonal Affective Disorder. , 1997, 167, 11-20.		6
632	IBZM-SPECT imaging of dopamine D2 receptors with typical and atypical antipsychotics. European Psychiatry, 1998, 13, 9s-14s.	0.2	6
633	Recurrent brief depression: A frequent syndrome in clinical practice. International Journal of Psychiatry in Clinical Practice, 2000, 4, 195-199.	2.4	6
634	A time of opportunity in schizophrenia. International Journal of Psychiatry in Clinical Practice, 2000, 4, 63-65.	2.4	6
635	Case report: Intestinal atonia as an unusual symptom of malignant catatonia responsive to electroconvulsive therapy. Schizophrenia Research, 2006, 84, 178-179.	2.0	6
636	Probing the association between serotonin-1A autoreceptor binding and amygdala reactivity in healthy volunteers. NeuroImage, 2018, 171, 1-5.	4.2	6
637	Low comorbid obsessive-compulsive disorder in patients with major depressive disorder – Findings from a European multicenter study. Journal of Affective Disorders, 2018, 227, 254-259.	4.1	6
638	Usage of Therapeutic Sleep Deprivation: A Survey in Psychiatric Hospitals in Austria, Germany, and Switzerland. Behavioral Sleep Medicine, 2019, 17, 713-720.	2.1	6
639	Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR. Frontiers in Molecular Neuroscience, 2019, 12, 172.	2.9	6
640	No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial. International Journal of Neuropsychopharmacology, 2021, 24, 171-180.	2.1	6
641	St John's wort extract: an effective and well-tolerated antidepressant. Primary Care and Community Psychiatry, 2001, 7, 39-42.	0.4	6
642	Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder. World Journal of Biological Psychiatry, 2022, 23, 715-718.	2.6	6
643	Incidence of Drug-Induced Delirium During Treatment With Antidepressants or Antipsychotics: A Drug Surveillance Report of German-Speaking Countries Between 1993 and 2016. International Journal of Neuropsychopharmacology, 2022, 25, 556-566.	2.1	6
644	Is Paranoid Schizophrenia the Most Common Subtype?. Psychopathology, 1999, 32, 98-106.	1.5	5
645	Psychosis as a possible side-effect of treatment with glatiramer acetate. International Journal of Neuropsychopharmacology, 2005, 8, 487-488.	2.1	5
646	Typical neuroleptics vs. atypical antipsychotics in the treatment of acute mania in a natural setting. International Journal of Neuropsychopharmacology, 2006, 9, 529.	2.1	5
647	How to improve adherence to antipsychotic treatment: Outcomes of the IMPROVING PATIENT OUTCOMES in psYchiaTry (IMPACT) Berlin 2009 meeting workshop. International Journal of Psychiatry in Clinical Practice, 2009, 13, 245-252.	2.4	5
648	Pharmacotherapy Update: Pregabalin in the Treatment of Generalized Anxiety Disorder. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S1103.	0.4	5

#	ARTICLE	IF	CITATIONS
649	Reduced connectivity in the uncinate fiber tract between the frontal cortex and limbic subcortical areas in social phobia. <i>European Psychiatry</i> , 2011, 26, 182-182.	0.2	5
650	Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression. <i>Journal of ECT</i> , 2017, 33, e31-e32.	0.6	5
651	Diversity matters: combinatorial information coding by GABAA receptor subunits during spatial learning and its allosteric modulation. <i>Cellular Signalling</i> , 2018, 50, 142-159.	3.6	5
652	Predicting Ventral Striatal Activation During Reward Anticipation From Functional Connectivity at Rest. <i>Frontiers in Human Neuroscience</i> , 2019, 13, 289.	2.0	5
653	Choosing among second-generation antidepressant treatments for depressed patients with cardiac diseases. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 134-148.	2.4	5
654	Attenuation Correction Approaches for Serotonin Transporter Quantification With PET/MRI. <i>Frontiers in Physiology</i> , 2019, 10, 1422.	2.8	5
655	Efficacy of Add-on Pregabalin in the Treatment of Patients with Generalized Anxiety Disorder and Unipolar Major Depression With an Early Nonresponse to Escitalopram: A Double-Blind Placebo-Controlled Study. <i>Pharmacopsychiatry</i> , 2019, 52, 193-202.	3.3	5
656	Brain glucose uptake during transcranial direct current stimulation measured with functional [18F]FDG-PET. <i>Brain Imaging and Behavior</i> , 2020, 14, 477-484.	2.1	5
657	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 571-577.	2.1	5
658	Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study. <i>CNS Spectrums</i> , 2021, 26, 290-298.	1.2	5
659	Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia. <i>NeuroImage: Clinical</i> , 2021, 32, 102813.	2.7	5
660	Subsyndromal generalised anxiety disorder: operationalisation and epidemiology – a systematic literature survey. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022, 26, 277-286.	2.4	5
661	Light Treatment in Depression(SAD, s-SAD & non-SAD). , 1999, , 409-416.		5
662	Drug treatment of seasonal affective disorder. , 2009, , 281-296.		5
663	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study. <i>European Neuropsychopharmacology</i> , 2022, 56, 100-111.	0.7	5
664	Depression: a long-term illness and its treatment. <i>International Clinical Psychopharmacology</i> , 1998, 13 Suppl 6, S23-6.	1.7	5
665	Treatment resistance in severe unipolar depression: no association with psychotic or melancholic features. <i>Annals of Clinical Psychiatry</i> , 2013, 25, 97-106.	0.6	5
666	Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2023, 273, 65-74.	3.2	5

#	ARTICLE	IF	CITATIONS
667	Sick leave duration as a potential marker of functionality and disease severity in depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022, 26, 406-416.	2.4	5
668	Is severe depression a different illness? The pharmacological evidence. <i>European Neuropsychopharmacology</i> , 1993, 3, 215-217.	0.7	4
669	P-4-32 IBZM-SPECT and D2 dopamine receptor occupancy: Different profiles with atypical neuroleptics. <i>European Neuropsychopharmacology</i> , 1995, 5, 337.	0.7	4
670	Sertindole and dopamine D2 receptor occupancy. <i>Biological Psychiatry</i> , 1997, 42, 161S.	1.3	4
671	Study of Family History in Seasonal Affective Disorder. <i>Neuropsychobiology</i> , 2001, 44, 65-69.	1.9	4
672	Relationship between Power Spectra of the Awake EEG and Psychomotor Activity Patterns Measured by Short-Term Actigraphy. <i>Neuropsychobiology</i> , 2003, 48, 176-181.	1.9	4
673	Self-poisonings with tricyclic antidepressants and selective serotonin reuptake inhibitors in Tehran, Iran. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 302-312.	2.6	4
674	Dysbindin gene (DTNBP1) in major depressive disorder (MDD) patients: Lack of association with clinical phenotypes. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 985-990.	2.6	4
675	Widespread Methodological Problems Limit Validity of Meta-Analytic Results. <i>Psychotherapy and Psychosomatics</i> , 2011, 80, 246-246.	8.8	4
676	Pharmacotherapy of anxiety disorders in German-speaking countries: current status and changes between 1994 and 2011. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 199-208.	3.2	4
677	Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 210-220.	2.6	4
678	Electroconvulsive therapy with S-ketamine anesthesia for catatonia in coexisting depression and dementia. <i>International Psychogeriatrics</i> , 2017, 29, 1223-1225.	1.0	4
679	Changes over time of the diagnostic and therapeutic characteristics of patients of a psychiatric intensive care unit in Austria. <i>Comprehensive Psychiatry</i> , 2019, 93, 20-26.	3.1	4
680	Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers. <i>Journal of Psychiatric Research</i> , 2021, 136, 543-551.	3.1	4
681	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. <i>Journal of Affective Disorders</i> , 2021, 286, 149-157.	4.1	4
682	Urological adverse drug reactions of psychotropic medication in psychiatric inpatients – A drug surveillance report from German-speaking countries. <i>Journal of Psychiatric Research</i> , 2021, 144, 412-420.	3.1	4
683	Mixed, melancholic, and anxious features in depression: a cross-sectional study of sociodemographic and clinical correlates. <i>Annals of Clinical Psychiatry</i> , 2014, 26, 243-53.	0.6	4
684	Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2023, 273, 51-63.	3.2	4

#	ARTICLE	IF	CITATIONS
685	Is treatment-resistant depression really resistant?. European Neuropsychopharmacology, 2022, 58, 44-46.	0.7	4
686	BDNF gene polymorphisms predicting treatment response to CBT-based rehabilitation of depression. European Neuropsychopharmacology, 2022, 58, 103-108.	0.7	4
687	Diagnosis and clinical course in mood disorders and depression subtypes. Depression, 1995, 3, 125-128.	0.6	3
688	EPOS: Increasing our understanding of the treatment of schizophrenia; Start of a prospective referenced cohort study of sertindole in clinical practice. International Journal of Psychiatry in Clinical Practice, 1997, 1, 197-202.	2.4	3
689	P.2.069 123I IBZM spect imaging of dopamine-2 receptors in psychotic patients treated with zotepine. European Neuropsychopharmacology, 1997, 7, S215.	0.7	3
690	What Young Men Do. International Journal of Psychiatry in Clinical Practice, 1998, 2, 156-156.	2.4	3
691	Treatment of depressive symptoms with quetiapine. Expert Review of Neurotherapeutics, 2003, 3, 417-423.	2.8	3
692	Psycho-pharmacotherapy for anxiety and obsessive-compulsive disorder: the issue of prolonged barbiturate retention. Current Medical Research and Opinion, 2009, 25, 2281-2285.	1.9	3
693	Mortality and employment after in-patient opiate detoxification. European Psychiatry, 2012, 27, 294-300.	0.2	3
694	Imaging brain circuits in anxiety disorders. Lancet Psychiatry, the, 2014, 1, 251-252.	7.4	3
695	Higher than recommended dosages of antipsychotics in male patients with schizophrenia are associated with increased depression but no major neurocognitive side effects: Results of a cross-sectional pilot naturalistic study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 75, 113-119.	4.8	3
696	High occupational level is associated with poor response to the treatment of depression: A replication study. European Neuropsychopharmacology, 2019, 29, 349-355.	0.7	3
697	On the suitability of medical analogies, from hypertension to broken leg. World Journal of Biological Psychiatry, 2019, 20, 171-172.	2.6	3
698	Big Data Guided Interventions: Predicting Treatment Response. , 2019, , 53-76.		3
699	How to prevent and manage hyperammonemic encephalopathies in valproate therapy. Journal of Affective Disorders Reports, 2021, 5, 100186.	1.7	3
700	Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study. CNS Spectrums, 2022, 27, 716-723.	1.2	3
701	Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany. International Journal of Psychiatry in Clinical Practice, 2021, 25, 1-10.	2.4	3
702	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. Journal of Affective Disorders, 2022, 296, 485-492.	4.1	3

#	ARTICLE	IF	CITATIONS
703	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110480.	4.8	3
704	Oxytocin receptor gene methylation as a molecular marker for severity of depressive symptoms in affective disorder patients. <i>BMC Psychiatry</i> , 2022, 22, .	2.6	3
705	The Impact of Theta-Burst Stimulation on Cortical GABA and Glutamate in Treatment-Resistant Depression: A Surface-Based MRSI Analysis Approach. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	2.9	3
706	Antidepressant side effects and adverse reactions. <i>Depression</i> , 1994, 2, 138-144.	0.6	2
707	D2 α Receptor imaging (SPECT) as a tool for measuring the efficacy and side-effect profile of treatment with neuroleptics. <i>Biological Psychiatry</i> , 1996, 39, 564.	1.3	2
708	Treatment of obsessive compulsive disorder: Algorithms for pharmacotherapy. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997, 1, S17-S23.	2.4	2
709	P.6.078 Personality traits in affective disorders as hints to biological disturbances. <i>European Neuropsychopharmacology</i> , 1997, 7, S288.	0.7	2
710	Focus on social functioning in depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 1998, 2, 241-243.	2.4	2
711	Atypical eating disorder in a male patient. <i>International Journal of Psychiatry in Clinical Practice</i> , 1999, 3, 137-139.	2.4	2
712	Rapid transcranial magnetic stimulation (r-TMS): A novel treatment option for seasonal affective disorder (SAD)?. <i>European Neuropsychopharmacology</i> , 2002, 12, 252.	0.7	2
713	Physical signs in psychiatry: a step towards evidence-based medicine. <i>International Journal of Psychiatry in Clinical Practice</i> , 2002, 6, 69-72.	2.4	2
714	Broadening the treatment indication: Is the term antipsychotic still justified?. <i>World Journal of Biological Psychiatry</i> , 2003, 4, 144-145.	2.6	2
715	Treatment challenges in the acute hospital setting. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 210-211.	2.6	2
716	Everyday Problems in Treating Depression: Focus on SNRIs. <i>CNS Spectrums</i> , 2008, 13, 4-4.	1.2	2
717	Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in schizophrenic or schizoaffective patients. <i>European Psychiatry</i> , 2011, 26, 1415-1415.	0.2	2
718	Social adjustment among treatment responder patients with mood disorders. <i>Journal of Affective Disorders</i> , 2013, 150, 961-966.	4.1	2
719	Pregabalin in Tourette's Syndrome: A Case Series. <i>American Journal of Psychiatry</i> , 2016, 173, 1242-1243.	7.2	2
720	Intramuscular maintenance treatment with ultra-high-dose long-acting injectable aripiprazole in an elderly patient suffering from chronic refractory schizophrenia: A case report. <i>European Psychiatry</i> , 2016, 33, S573-S573.	0.2	2

#	ARTICLE	IF	CITATIONS
721	Editorial. International Journal of Psychiatry in Clinical Practice, 2017, 21, 1-1.	2.4	2
722	Personalised and precision psychiatry: what do the CINP bipolar guidelines suggest?. International Journal of Psychiatry in Clinical Practice, 2019, 23, 80-81.	2.4	2
723	Molecular neuroimaging of the serotonergic system with Positron Emission Tomography. Handbook of Behavioral Neuroscience, 2020, 31, 175-194.	0.7	2
724	Case Report: Bupropion Reduces the [123I]FP-CIT Binding to Striatal Dopamine Transporter. Frontiers in Psychiatry, 2021, 12, 631357.	2.6	2
725	Monoamino Oxidase A Gene Single-Nucleotide Polymorphisms and Methylation Status and the Risk of Violent Suicide Attempts in Affective Disorder Patients. Frontiers in Psychiatry, 2021, 12, 667191.	2.6	2
726	Nicht-trizyklische Antidepressiva. , 1993, , 105-268.		2
727	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. International Journal of Neuropsychopharmacology, 2021, , .	2.1	2
728	Psychopharmakotherapie â€“ Klinisch-empirische Grundlagen. , 2011, , 731-766.		2
729	Dexamethasone Suppression Test Combined with Total Sleep Deprivation in Depressed Patients. Psychopathology, 1983, 16, 17-25.	1.5	2
730	Pharmacokinetics of chlorprothixene after single intravenous and oral administration of three galenic preparations. Arzneimittelforschung, 1996, 46, 247-50.	0.4	2
731	Atypical antipsychotics in mood disorders. International Clinical Psychopharmacology, 2002, 17 Suppl 3, S1-10.	1.7	2
732	Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia. International Clinical Psychopharmacology, 2002, 17 Suppl 4, S19-26.	1.7	2
733	The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs. Journal of Affective Disorders, 2022, 312, 225-234.	4.1	2
734	Regional gene expression patterns are associated with task-specific brain activation during reward and emotion processing measured with functional MRI. Human Brain Mapping, 2022, 43, 5266-5280.	3.6	2
735	Judgement of the hypothalamic-pituitary-adrenocortical function in psychiatric patients by betamethasone-induced cortisol suppressibility. Journal of Neural Transmission, 1988, 74, 161-174.	2.8	1
736	Treatment indications for light therapy. Acta Neuropsychiatrica, 1995, 7, 44-46.	2.1	1
737	Involvement of mesial-temporal structures in rapid cycling mood disorders?. Human Psychopharmacology, 1995, 10, 475-480.	1.5	1
738	[123I] Î²-CIT SPECT in drug-free depressed patients with seasonal affective disorder. Biological Psychiatry, 1997, 42, 168S.	1.3	1

#	ARTICLE	IF	CITATIONS
739	IBZM-SPECT imaging of dopamine D2 receptors with typical and atypical antipsychotics. <i>European Psychiatry</i> , 1998, 13, 9s-14s.	0.2	1
740	Quetiapine in a delusional depressed elderly patient: no EPS and a favourable outcome. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 199-200.	2.1	1
741	Myths and Facts about Post Traumatic Stress Disorder. <i>World Journal of Biological Psychiatry</i> , 2004, 5, 64-65.	2.6	1
742	Is SAD Lost to SAD?. <i>CNS Spectrums</i> , 2005, 10, 622-622.	1.2	1
743	Management of acutely ill patients in the hospital setting: focus on quetiapine. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007, 11, 61-72.	2.4	1
744	CREB-regulated diurnal activity patterns are not indicative for depression-like symptoms in mice and men. <i>Medical Hypotheses</i> , 2008, 70, 117-121.	1.5	1
745	Anxiety Scores are Related to Amygdala Activity Induced by Facial Attractiveness and Emotional Expressions. <i>NeuroImage</i> , 2009, 47, S48.	4.2	1
746	P.1.16 Serotonin-1A receptor binding potential in dorsal raphe nuclei predicts orbitofrontal reactivity in healthy subjects. <i>European Neuropsychopharmacology</i> , 2009, 19, S15-S16.	0.7	1
747	P.2.c.002 Serotonin or noradrenalin reuptake inhibition in seasonal affective disorder: escitalopram versus reboxetine. <i>European Neuropsychopharmacology</i> , 2009, 19, S404.	0.7	1
748	The proof of efficacy in psychopharmacology: clinical studies, metaanalysis and evidence-based medicine. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 1-1.	3.2	1
749	Segmentation of [11C]DASB and [carbonyl-11C]WAY-100635 PET brain images using linear discriminant analysis. <i>NeuroImage</i> , 2010, 52, S155-S156.	4.2	1
750	FC29-05 - Season, sunlight, and brain serotonin function. <i>European Psychiatry</i> , 2011, 26, 1981-1981.	0.2	1
751	The viennese psychiatric intensive care unit - diagnostic distribution. <i>European Psychiatry</i> , 2011, 26, 1763-1763.	0.2	1
752	Orbitofrontal hyperactivity in social anxiety disorder patients: An fmri study. <i>European Psychiatry</i> , 2011, 26, 179-179.	0.2	1
753	Testosterone, Neural Circuits, and Male Depression. <i>Biological Psychiatry</i> , 2014, 76, 272-273.	1.3	1
754	PM478. Imaging the effects of d-amphetamine in the human brain for modelling dopaminergic alterations in schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, 74-74.	2.1	1
755	Attenuation of habenulaâ€“default mode network connectivity by selective serotonin reuptake inhibitors, a pharmacological hybrid PET/MR study. <i>European Neuropsychopharmacology</i> , 2016, 26, S317.	0.7	1
756	Case Report. <i>Journal of ECT</i> , 2017, 33, e2-e3.	0.6	1

#	ARTICLE	IF	CITATIONS
757	Monoamine oxidase A distribution volume as a correlate for electroconvulsive therapy " preliminary results. <i>European Neuropsychopharmacology</i> , 2017, 27, S708-S709.	0.7	1
758	Editorial issue 4/2019. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 237-237.	2.4	1
759	Oral Ketamine as a Treatment Option in Patients With Treatment Resistant Depression and Comorbid Arterial Hypertension. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 418-420.	1.4	1
760	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. <i>Current Medicinal Chemistry</i> , 2021, 28, 4296-4320.	2.4	1
761	Psychopharmakotherapie " Klinisch-empirische Grundlagen. , 2008, , 627-667.		1
762	Obituary " Prof. Dr. Hanns Hippus (1925 " 2021). <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 856-857.	2.1	1
763	Reduzierte Amplitude zirkadianer Hormonprofile bei Patienten mit saisonal abhÄngiger Depression (SAD). , 1992, , 356-359.		1
764	Sicherheit und antidepressive Wirksamkeit von spezifischen Serotonin-Wiederaufnahmehemmern (SSRIs). , 1993, , 163-182.		1
765	Quantitatives EEG und Ansprechen auf therapeutischen Schlafentzug bei depressiven Patienten. , 1993, , 217-220.		1
766	Behandlungsergebnisse mit präsynaptischen und postsynaptischen Dopamin-Agonisten bei Minussymptomatik. , 1994, , 221-239.		1
767	Kombination von Schlafentzug und Lichttherapie zur Behandlung depressiver StÄrungen. , 1996, , 69-80.		1
768	(Potentielle) Antipsychotika mit neuartigen Wirkmechanismen. , 1998, , 489-499.		1
769	Psychopharmakotherapie " klinisch-empirische Grundlagen. , 2017, , 795-842.		1
770	Letter to BJPsych in response to Horowitz and Moncrieff. <i>British Journal of Psychiatry</i> , 2021, 219, 619-620.	2.8	1
771	IBZM-SPECT imaging of dopamine D(2) receptors with typical and atypical antipsychotics. <i>European Psychiatry</i> , 1998, 13 Suppl 1, 9s-14s.	0.2	1
772	A gap analysis for future supply of and demand for psychiatrists in Austria. <i>Journal of Mental Health Policy and Economics</i> , 2014, 17, 9-18.	0.6	1
773	Factors associated with sick leave duration in patients suffering from major depressive disorder initiating antidepressant treatment: a real-world evidence study in Germany and Spain. <i>International Journal of Psychiatry in Clinical Practice</i> , 2023, 27, 59-68.	2.4	1
774	Hormonal markers of response to antidepressive treatment. <i>European Neuropsychopharmacology</i> , 1993, 3, 321-322.	0.7	0

#	ARTICLE	IF	CITATIONS
775	Risperidone in the treatment of Gilles de la Tourette Syndrome. European Neuropsychopharmacology, 1996, 6, S4-163.	0.7	0
776	S.07.02 Therapeutic sleep deprivation: Lessons for psychopharmacology?. European Neuropsychopharmacology, 1997, 7, S91-S92.	0.7	0
777	P.6.079 Risperidone in Gilles de la Tourette syndrome patients unresponsive to typical neuroleptics. European Neuropsychopharmacology, 1997, 7, S288.	0.7	0
778	P.6.083 Enhanced striatal dopamine transporter activity in drug naive and previously treated patients with gilles de la tourette syndrome (GTS): A [123I]-β-CIT SPECT-study. European Neuropsychopharmacology, 1997, 7, S289-S290.	0.7	0
779	P02.188 1H-Magnetic resonance spectroscopy at 3.0 tesla reveals reduced n-acetyl aspartate, choline and myo-inositol levels in depression. European Psychiatry, 2000, 15, 372s-372s.	0.2	0
780	Sonstige biologische Therapieverfahren (EKT, TMS, VNS, Schlafentzugsbehandlung, Lichttherapie): theoretische und empirische Grundlagen sowie klinische Anwendungsprinzipien. , 2003, , 610-629.		0
781	Clinical efficacy in depression. , 2005, , 123-131.		0
782	S.07.04 Progesterone and estradiol plasma levels modulate serotonin-1A binding in the human brain. European Neuropsychopharmacology, 2008, 18, S168.	0.7	0
783	Pharmacological Properties of Psychopharmaca in Relationship to their Clinical Indications. European Psychiatry, 2009, 24, .	0.2	0
784	Neuroimaging Findings and Diagnosis. European Psychiatry, 2009, 24, .	0.2	0
785	SPECT Imaging. , 2010, , 1266-1270.		0
786	Treatment Resistance in Depression. European Psychiatry, 2011, 26, 2022-2022.	0.2	0
787	Meta-analysis on the dissection table. European Psychiatry, 2011, 26, 1240-1240.	0.2	0
788	SS06-01 - Are we getting the most out of combination therapy in the short-term and long-term treatment of mania?. European Psychiatry, 2011, 26, 2181-2181.	0.2	0
789	FC07-06 - Differences in the modulatory role of escitalopram and citalopram revealed by effective connectivity analysis. European Psychiatry, 2011, 26, 1851-1851.	0.2	0
790	Database of MNI stereotactic coordinates for deep brain stimulation targets in neuropsychiatric disorders. European Psychiatry, 2011, 26, 1149-1149.	0.2	0
791	The viennese psychiatric intensive care unit - therapeutic modalities. European Psychiatry, 2011, 26, 1764-1764.	0.2	0
792	Antidepressant self-poisonings in iran. European Psychiatry, 2011, 26, 1268-1268.	0.2	0

#	ARTICLE	IF	CITATIONS
793	FC04-06 - Candidate gene association study of suicidality in treatment resistant MDD. European Psychiatry, 2011, 26, 1833-1833.	0.2	0
794	JS03-01 - Diagnosis and Treatment of Depression in Europe. European Psychiatry, 2011, 26, 2003-2003.	0.2	0
795	JS02-01 - Psychiatric intensive care. European Psychiatry, 2011, 26, 1999-1999.	0.2	0
796	Antipsychotics in obsessive-compulsive disorder - an auspicious approach for treatment-resistant patients?. European Psychiatry, 2011, 26, 1236-1236.	0.2	0
797	SS05-03 - Proven antidepressant efficacy of agomelatine against the full range of symptoms. European Psychiatry, 2011, 26, 2179-2179.	0.2	0
798	Biological alterations during remission of major depressive disorder. European Psychiatry, 2011, 26, 633-633.	0.2	0
799	Are there structural brain changes following 10 days of SSRI administration investigated by voxel-based morphometry?. European Psychiatry, 2011, 26, 913-913.	0.2	0
800	Increased functional coupling between basal ganglia and cingulate and prefrontal cortex during resting state conditions in remitted major depressive disorder. European Psychiatry, 2011, 26, 915-915.	0.2	0
801	Cortisol plasma levels are associated with serotonin - 1A receptor binding in postmenopausal women. European Psychiatry, 2011, 26, 933-933.	0.2	0
802	P.1.e.027 Serotonin -1A receptor binding in the dorsal raphe nucleus is associated with hippocampal grey matter volume. European Neuropsychopharmacology, 2011, 21, S318-S319.	0.7	0
803	P.1.e.028 Resting -state functional connectivity of the raphe nuclei. European Neuropsychopharmacology, 2011, 21, S319-S320.	0.7	0
804	P.4.002 Serotonin transporter ratio between raphe nuclei and projection areas predicts SSRI treatment response in major depression. European Neuropsychopharmacology, 2012, 22, S85.	0.7	0
805	P.2.b.044 Serotonin transporter association between dorsal raphe and ventral striatum is diminished in major depression. European Neuropsychopharmacology, 2013, 23, S345.	0.7	0
806	P.1.i.047 Interregional changes in serotonin transporter availability upon treatment with selective serotonin reuptake inhibitors. European Neuropsychopharmacology, 2015, 25, S327-S328.	0.7	0
807	P.1.i.034 Gene expression and protein distribution of serotonergic key proteins in the human brain revealed by PET in vivo and postmortem quantification. European Neuropsychopharmacology, 2015, 25, S319-S320.	0.7	0
808	Editorial. International Journal of Psychiatry in Clinical Practice, 2015, 19, 227-227.	2.4	0
809	P.1.i.037 Effects of norepinephrine transporter gene variants on protein binding in patients with ADHD using PET. European Neuropsychopharmacology, 2015, 25, S321-S322.	0.7	0
810	PS168. Hybrid PET/MR imaging of serotonin transporter occupancy and brain activation to elucidate the mechanism of action of selective serotonin reuptake inhibitors. International Journal of Neuropsychopharmacology, 2016, 19, 60-61.	2.1	0

#	ARTICLE	IF	CITATIONS
811	Estradiol level changes correlate with changes in mean diffusivity and fractional anisotropy values in female-to-male transsexuals. <i>European Neuropsychopharmacology</i> , 2016, 26, S202.	0.7	0
812	P.1.015 Surface-based clustering of serotonergic and adrenergic receptor mRNA expression in the human cortex. <i>European Neuropsychopharmacology</i> , 2016, 26, S15.	0.7	0
813	International Journal of Psychiatry in Clinical Practice. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016, 20, 209-209.	2.4	0
814	A European psychopharmacology curriculum: The young psychiatrist's point of view. <i>European Psychiatry</i> , 2016, 33, S63-S63.	0.2	0
815	Norepinephrine transporter gene and protein expression of the human brain investigated with postmortem data and PET. <i>European Neuropsychopharmacology</i> , 2017, 27, S73-S74.	0.7	0
816	Systematic evaluation of dose-escalation strategies after initial non-response to standard-dose pharmacotherapy in schizophrenia. <i>European Psychiatry</i> , 2017, 41, S193-S193.	0.2	0
817	Alternating intravenous racemic ketamine and electroconvulsive therapy in treatment resistant depression: A case report. <i>European Psychiatry</i> , 2017, 41, S522-S522.	0.2	0
818	Prevention of seasonal affective disorder: results of a survey in German-speaking countries. <i>European Journal of Public Health</i> , 2017, 27, .	0.3	0
819	Influence of serotonergic gene variants on serotonin transporter binding in ADHD. <i>European Neuropsychopharmacology</i> , 2017, 27, S707.	0.7	0
820	Reduced gray matter in subcortical brain regions in MDD: preliminary results of an ultra-high field 7 Tesla MRI Study. <i>European Neuropsychopharmacology</i> , 2017, 27, S719-S720.	0.7	0
821	Investigating dose dependency of ketamine binding on the serotonin transporter with positron emission tomography. <i>European Neuropsychopharmacology</i> , 2017, 27, S779.	0.7	0
822	Editorial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2018, 22, 1-1.	2.4	0
823	Editorial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2018, 22, 241-241.	2.4	0
824	Editorial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 83-83.	2.4	0
825	A thank-you note from the Chief-Editor. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 254-257.	2.6	0
826	Editorial issue 3/2019. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 163-163.	2.4	0
827	Characterization of pharmacological response to selective serotonin reuptake inhibitors using clustering of resting-state hybrid PET/MR data. <i>European Neuropsychopharmacology</i> , 2019, 29, S603-S604.	0.7	0
828	Editorial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 1-1.	2.4	0

#	ARTICLE	IF	CITATIONS
829	Attrition in treatment-resistant depression. International Clinical Psychopharmacology, 2019, 34, 161-169.	1.7	0
830	Torgny Svensson, a superb mind and an inspiring colleague. International Journal of Neuropsychopharmacology, 2020, 23, 543-544.	2.1	0
831	Editorial. International Journal of Psychiatry in Clinical Practice, 2020, 24, 329-329.	2.4	0
832	Editorial 3. International Journal of Psychiatry in Clinical Practice, 2020, 24, 217-218.	2.4	0
833	Editorial 2. International Journal of Psychiatry in Clinical Practice, 2021, 25, 107-108.	2.4	0
834	Wirksamkeit von Silexan bei generalisierter Angststörung: Re-Analyse einer randomisierten klinischen Prüfung mit modernen statistischen Methoden. , 2021, 42, .		0
835	Aminpräkursoren. , 2002, , 627-649.		0
836	Serotonin-selektive Antidepressiva(SSRI, DSA). , 2002, , 223-363.		0
837	Psychiatrische Erkrankungen. , 2003, , 1265-1384.		0
838	Notfälle in der Psychiatrie. , 2003, , 429-442.		0
839	Demenzen. , 2004, , 250-280.		0
840	Diagnose und Behandlung der subsyndromalen SAD. , 2004, , 33-40.		0
841	Epidemiologie der saisonal abhängigen Depression (SAD) und ihrer subsyndromalen Form (S-SAD). , 2004, , 23-32.		0
842	Prolaktin. , 2004, , 88-108.		0
843	Bipolare affektive Störungen. , 2004, , 189-222.		0
844	Pharmakodynamik. , 2004, , 368-376.		0
845	Sonstige biologische Therapieverfahren (EKT, Schlafentzugsbehandlung, Lichttherapie, TMS, VNS) – Theoretische und empirische Grundlagen sowie klinische Anwendungsprinzipien. , 2008, , 669-690.		0
846	In Reply. Deutsches Ärzteblatt International, 2013, 110, 610-1.	0.9	0

#	ARTICLE	IF	CITATIONS
847	The Impact of Genetic Polymorphisms on Neuroreceptor Imaging. , 2014, , 149-178.		0
848	Neuroimaging in Seasons and Winter Depression. , 2014, , 209-222.		0
849	Therapeutischer Schlafentzug und Resistenz auf Antidepressiva â€” Neuroendokrinologische und klinische Befunde. , 1992, , 446-448.		0
850	Objektivierung der quantitativen Lichtexposition wÃ¤hrend Lichttherapie durch kontinuierliche photometrische Aufzeichnung. , 1993, , 268-271.		0
851	Therapeutischer Schlafentzug und antidepressive Medikation. , 1996, , 55-67.		0
852	Schlafentzug bei Therapieresistenz auf Antidepressiva. , 1996, , 107-122.		0
853	Nebenwirkungen der Lichttherapie bei der Behandlung psychischer Erkrankungen. , 1996, , 232-236.		0
854	RÃ¼ckfallverhÃ¼tung nach Schlafentzug. , 1996, , 466-469.		0
855	Metabolismustheorie des therapeutischen Schlafentzugs. , 1996, , 460-465.		0
856	Psychopharmakotherapie â€” klinisch-empirische Grundlagen. , 2015, , 1-48.		0
857	Hirnstimulationsverfahren, Elektrokonvulsionstherapie. , 2016, , 1-23.		0
858	Lichttherapie. , 2016, , 1-8.		0
859	Schlafentzugsbehandlung. , 2016, , 1-7.		0
860	Elektrokonvulsionstherapie, Hirnstimulationsverfahren. , 2017, , 1-46.		0
861	Lichttherapie. , 2017, , 895-901.		0
862	Schlafentzugsbehandlung. , 2017, , 889-894.		0
863	Elektrokonvulsionstherapie, Hirnstimulationsverfahren. , 2017, , 843-887.		0
864	Effects of lavender oil on insomnia in patients with anxiety disorders â€” a meta-analysis. Planta Medica, 2019, 85, .	1.3	0

#	ARTICLE	IF	CITATIONS
865	Neuroimaging in Seasons and Winter Depression. , 2021, , 245-259.		0
866	Doseâ€response relationship of selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica, 2020, 142, 427-429.	4.5	0
867	Prinzipien der Psychopharmakotherapie. , 2005, , 1311-1317.		0
868	Rezidivierende kurze depressive Episoden und Rapid Cycling. , 2005, , 503-510.		0
869	Prinzipien der Psychopharmakotherapie. , 2007, , 1474-1481.		0
870	Nichtpharmakologische somatische Therapien. , 2008, , 727-750.		0
871	Editorial 4. International Journal of Psychiatry in Clinical Practice, 2021, 25, 331-332.	2.4	0
872	HL-A-antigens, schizophrenia and brain atrophy. British Journal of Psychiatry, 1980, 137, 398-9.	2.8	0
873	Editorial 1. International Journal of Psychiatry in Clinical Practice, 2022, 26, 1-2.	2.4	0
874	Initiating Antidepressant Medication: What is the Most Important Factor?. Advances in Therapy, 2022, , 1.	2.9	0
875	Cariprazine for treating psychosis: an updated meta-analysis. International Journal of Psychiatry in Clinical Practice, 2022, , 1-3.	2.4	0
876	Editorial 2. International Journal of Psychiatry in Clinical Practice, 0, , 1-2.	2.4	0